Clinical Trials Manager ©

  Contact webmaster
  Updated 09/03/2009 17:42:24

Trial status: Active

Trials found: 388

Clinical Trials Network : Therapeutic group
Cardiovascular
IM/Other
Liver Disease

Department Division
Anesthesiology Other
Dermatology Cosmetic Dermatology
Dermatology Clinic
General Practice
Pediatrics
Medicine Cardiology
Digestive & Liver Diseases
Endocrinology
General Medicine
Hematology and Oncology
Infectious Diseases
Medical Oncology
Nephrology
Preventive Medicine & Nutrition
Pulmonary Cardiology
Pulmonary, Allergy & Critical Care Medicine
Rheumatology
Neurological Surgery Epilepsy Movement
Neuro Surgeon
Neurooncology
Spine
Neurology Dementia and Aging
Epilepsy
G H Sergievsky Center
General Neurology
Movement Disorders
Movement Disorders/neuromuscular
Multiple Sclerosis and Demyelinating Diseases
Neuromuscular Disease
Neurooncology
Stroke and Critical Care
Obstetrics and Gynecology Family Planning & Preventive Services
Gynecologic Oncology
Maternal Fetal Medicine
Menopause
Obstetrics and Gynecology
Reproduction and Endocrinology
Ophthalmology Glaucoma
Macula Surgical & Medical Retinal Disease
Ophthalmology
Other
Orthopedic Surgery Lower Extremity and Reconstruction
Otolaryngology/head and Neck Surgery Head & Neck Surgery
Pathology Hemopathology
Pediatrics Autoimmune & Molecular Diseases
Cardiology
Endocrinology
Gastroenterology & Nutrition
Hematology and Blood and Marrow Transplant
Infectious Diseases
Neonatology & Perinatal Medicine
Oncology
Pulmonary
Rheumatology
Psychiatry Behavioral Medicine
Child Psychiatry
Geriatrics
Neuroscience
Other
Substance Abuse
Radiation Oncology Radiation Oncology
Radiology Interventional Radiology
Neurosurgery
School Of Dental and Oral Surgury Periodontics
Surgery Allen General Surgery
Cardiothoracic Surgery
Center For Liver Disease & Transplantation
Surgical Oncology
Surgical Specialties
Vascular Surgery
Urology Oncology


Trial details


Clinical Trials Network
Group : Cardiovascular
ACCOMPLISH - Prospective, multinational, multicenter, double-blind, randomized, active-controlled, trial to compare effects of Lotrel to benazepril & hydrochlorothiazide combined on reduction of cardiovascular morbidity & morality patients w/ high risk hy
 
Principal Investigator: Mathew Maurer  
Start date: 03/24/2004
End date: 12/24/2009
to request information from Principal Investigator.
   Top of page
ACCORD - N01 HC 95184/Action to Control Cardiovascular Risk in Diabetes
 
Principal Investigator: J. Thomas Bigger, Jr.  
Website: www.accord-ne.org
Start date: 09/30/1999
End date: 04/30/2010
to request information from Principal Investigator.
   Top of page
ACCORD-Eye - Action to Control Cardiovascular Risk in Diabetes -- Eye Substudy
 
Principal Investigator: J. Thomas Bigger, Jr.  
Website: www.accord-ne.org
Start date: 11/01/2003
End date: 04/30/2010
to request information from Principal Investigator.
   Top of page
RO4607381 - Phase III, double-blind, randomized placebo-controlled study, to evaluate the effects of RO4607381 on cardiovascular (CV) risk in stable CHD patients, with a documented recent Acute Coronary Syndrome (ACS).
 
Principal Investigator: J. Thomas Bigger, Jr.  
Start date: 12/15/2008
End date: 06/30/2011
to request information from Principal Investigator.
   Top of page


Clinical Trials Network
Group : IM/Other
ITNTWK - Proleukin and Rapamune in Recent-onset Type 1 Diabetes Mellitus: Phase 1
 
Principal Investigator: Robin S. Goland (CTN)  
Start date: 10/15/2008
End date: 09/14/2011
to request information from Principal Investigator.
   Top of page


Clinical Trials Network
Group : Liver Disease
ENTECAVIR-INCOMPLETE - FUNDED ACCOUNT: Protocol No. AI463-026-045 A Phase III Study of the Comparison of Entecavir to Lamivudine in Chronic Hepatitis B Subjects with Incomplete Response to Current Lamivudine Therapy
 
Principal Investigator: Robert S. Brown  
Start date: 04/16/2002
End date: 02/02/2010
to request information from Principal Investigator.
   Top of page


Department :Anesthesiology
Division : Other
Fixed dose of sucutaneous methylnaltrexone in adults with advanced illness and opioid induced constipation.
 
Principal Investigator: Michael Weinberger  
Start date: 05/28/2008
End date: 11/30/2013
to request information from Principal Investigator.
   Top of page


Department :Dermatology
Division : Cosmetic Dermatology
Early Diagnosis of Melanoma - Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells.
 
Principal Investigator: Julide T Celebi  
Start date: 04/10/2008
End date: 10/31/2009
to request information from Principal Investigator.
   Top of page


Department :Dermatology
Division : Dermatology Clinic
**STUDY MGR**A Phase II Pivotal Trial to Evaluate the Safety and Efficacy of Nitrogen Mustard (NM) 0.02% Ointment Formulations in Patients with Stage I or IIA Mycosis Fungoides (MF)
 
Principal Investigator: Elizabeth Knobler  
Start date: 06/12/2007
End date: 12/31/2009
to request information from Principal Investigator.
   Top of page
Nitrogen Mustard 0.04% - Open Label Six Month Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (NM) 0.04% Ointment Formulation in Patients with Stage I or IIA Mycosis Fungoides (MF) Who Have Completed an Initial 12 Month Treatment with Nitrog
 
Principal Investigator: Elizabeth Knobler  
Start date: 02/14/2008
End date: 09/30/2009
to request information from Principal Investigator.
   Top of page


Department :Dermatology
Division : General Practice
**STUDY MGR** An Un-blinded Exploratory Study to Evaluate a Cutaneous Incisional Wound Model of Mast Cell Infiltration in Healthy Volunteers and Idiopathic Pulmonary Fibrosis (IPF) Patients
 
Principal Investigator: Julian Mackay-Wiggan  
Start date: 12/13/2007
End date: 06/30/2010
to request information from Principal Investigator.
   Top of page
M03-658 - Multicenter, Open-Label, Continuation Study in Moderate to Severe Chronic plaque Psoriasis Subjects who Completed a Preceding Psoriasis Clinical Study with Adalimumab
 
Principal Investigator: Julian Mackay-Wiggan  
Website: smills@parabio.com
Start date: 09/14/2005
End date: 09/06/2009
to request information from Principal Investigator.
   Top of page
Observational Post-marketing Safety Surveillance Registry of Enbrel (etanercept) for Treatment of Psoriasis
 
Principal Investigator: Julian Mackay-Wiggan  
Start date: 07/20/2006
End date: 02/28/2016
to request information from Principal Investigator.
   Top of page
Phase III Randomized, Evaluator-Blind, Parallel Group Study of the Safety and Efficacy of Itraconazole Tablets, Itraconazole Capsules and Placebo in the Treatment of Onychomycosis of the Toenail
 
Principal Investigator: Julian Mackay-Wiggan  
Start date: 05/11/2007
End date: 11/30/2010
to request information from Principal Investigator.
   Top of page


Department :Dermatology
Division : Pediatrics
APPLES - Prospective Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Tacrolimus Ointment for the Treatment of Atopic Dermatitis
 
Principal Investigator: Kimberly D. Morel  
Start date: 11/22/2005
End date: 09/30/2020
to request information from Principal Investigator.
   Top of page
Prospective, Multicenter, within Subject Controlled Study to Evaluate the Effect of Apligraf in Nonhealing Wounds of Subjects with Junctional or Dystrophic Epidermolysis Bullosa
 
Principal Investigator: Kimberly D. Morel  
Start date: 05/11/2008
End date: 09/30/2009
to request information from Principal Investigator.
   Top of page


Department :Medicine
Division : Cardiology
**STUDY MGR*A Rdmzd, OL Study to Compare the Safety and Efficacy of Conversion From A Calcineurin Inhibitor to Sirolimus Verus Continued Use of a Calcineurin Inhibitor in Cardiac Transplant Rcpnts w/Mild to Moderate Renal Insufficiency
 
Principal Investigator: Donna Mancini  
Start date: 12/15/2006
End date: 06/30/2011
to request information from Principal Investigator.
   Top of page
123I-mIBG - Open-Label, Multicenter, Phase 3 study Evaluating the Prognostic Usefulness of 123 I-mlBG Scintigraphy for identifying subjects with heart failure who will experience an adverse cardiac event
 
Principal Investigator: Sabahat Bokhari  
Start date: 08/25/2005
End date: 12/31/2010
to request information from Principal Investigator.
   Top of page
ADAPT DES - ADAPT DES Study: Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents
 
Principal Investigator: Giora Weisz  
Start date: 06/04/2008
End date: 01/31/2015
to request information from Principal Investigator.
   Top of page
CHAMPION - CHAMPION: CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients.
 
Principal Investigator: Donna Mancini  
Start date: 07/09/2008
End date: 05/01/2012
to request information from Principal Investigator.
   Top of page
CHAMPION - Clinical Trial Comparing Cangrelor to Clopidogrel in Subjects who Require Percutaneous Coronary Intervention
 
Principal Investigator: George Dangas  
Start date: 04/24/2008
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
COSTAR II - Cobalt Chromium Stent with Antiproliferative for Restenosis II Trial
 
Principal Investigator: Michael Collins  
Website: unknown
Start date: 06/08/2005
End date: 12/31/2009
to request information from Principal Investigator.
   Top of page
CREST - RO1 NS38384/Carotid Revascularization Endarterectomy vs. Stent Trial
 
Principal Investigator: William Gray  
Start date: 10/10/2008
End date: 12/31/2011
to request information from Principal Investigator.
   Top of page
CUPID Trial - Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease
 
Principal Investigator: Donna Mancini  
Start date: 05/04/2007
End date: 11/30/2012
to request information from Principal Investigator.
   Top of page
Complete SE Registry - **STUDY MANAGER** Complete SE Registry: Percutaneous interventional treatment of iliac artery lesions using the Medtronic Complete® Self-Expanding (SE) Iliac Stent.
 
Principal Investigator: William Gray  
Start date: 04/15/2008
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
DETERMINE - Defibrillators to Reduce Risk by Magnetic Resonance Imaging Evaluation
 
Principal Investigator: Fredrick A Ehlert  
Start date: 09/12/2008
End date: 01/07/2013
to request information from Principal Investigator.
   Top of page
Double-blind, prospective, randomized, placebo-controlled study to determine the tolerability, efficacy, safety, and dose range of intramyocardial injections of G-CSF mobilized Auto-CD34+ cells for reduction of angina episodes in pts with refractory
 
Principal Investigator: Warren Sherman  
Start date: 08/14/2006
End date: 02/28/2011
to request information from Principal Investigator.
   Top of page
EMPIRE - **STUDY MANAGER** Embolic Protection with Reverse Flow Study of the Gore Neuro Protection System in Carotid Stenting of Subjects at High Risk for Carotid Endarterectomy
 
Principal Investigator: William Gray  
Start date: 10/08/2007
End date: 03/31/2010
to request information from Principal Investigator.
   Top of page
ENDEAVOR 4 - **STUDY MANAGER** Randomized, controlled trial of the medtronic endeavor drug(ABT-578) eluting coronary stent system vs. the Taxus Paclitaxel-eluting coronary stent system in de novo native coronary lesions
 
Principal Investigator: Jeffrey W. Moses  
Start date: 05/12/2005
End date: 11/30/2010
to request information from Principal Investigator.
   Top of page
ENDEAVOR SVS - **STUDY MANAGER** Endeavor SVS Registry: A Clinical Evaluation of the Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System in the Treatment of Single De novo Lesions in Small Diameter Native Coronary Arteries.
 
Principal Investigator: Jeffrey W. Moses  
Start date: 06/10/2008
End date: 10/31/2013
to request information from Principal Investigator.
   Top of page
EVEREST II - **STUDY MANAGER** A study of the Evalve Cardiovascular Valve repair system (CVRS) endovascular valve edge-to-edge repair study
 
Principal Investigator: William Gray  
Start date: 03/21/2005
End date: 09/30/2009
to request information from Principal Investigator.
   Top of page
Lightlab M4 - **STUDY MANAGER** Evaluation of the M4 System for Imaging Stented Coronary Arteries-Device trial
 
Principal Investigator: Jeffrey W. Moses  
Start date: 10/27/2008
End date: 04/30/2011
to request information from Principal Investigator.
   Top of page
MYOHEART - Myogenesis Heart Efficiency and Regeneration Trial
 
Principal Investigator: Warren Sherman  
Start date: 07/11/2006
End date: 01/31/2012
to request information from Principal Investigator.
   Top of page
MediGuide Trial - **STUDY MANAGER** MediGuide Trial: Medical Positioning System (MPS) In Conjunction with Guided Measurement Catheter (GMC™) Feasibility Study in Clinical Routine.
 
Principal Investigator: Giora Weisz  
Start date: 03/09/2008
End date: 09/30/2009
to request information from Principal Investigator.
   Top of page
Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of KW-3902 Injectable Emulsion on Heart Failure Signs and Symptoms, Diuresis, Renal Function, and Clinical Outcomes in Subjects Hospitalized with Worsening Renal Function
 
Principal Investigator: Paolo C. Colombo  
Start date: 12/19/2007
End date: 07/31/2011
to request information from Principal Investigator.
   Top of page
Optivol Study - Correlation Between T Wave Alternans and Intrathoracic Impedance Measurements Using Optivol T Wave Alternans/Optivol Study.
 
Principal Investigator: Jose Dizon  
Start date: 04/28/2007
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
PARTNER - **STUDY MANAGER** The PARTNER Trial: Placement of Aortic Transcatheter Valves Trial
 
Principal Investigator: Martin Leon  
Start date: 05/29/2007
End date: 11/30/2009
to request information from Principal Investigator.
   Top of page
PROTECT-II - multicenter, randomized, double-blind, placebo-controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure signs and renal impairment who are hospi
 
Principal Investigator: Maryjane A. Farr  
Start date: 02/14/2008
End date: 09/30/2010
to request information from Principal Investigator.
   Top of page
Pacing Chronotropic Incompetence - Cardiovascular and Neurohormonal Effects of Faster Atrial Pacing Rate For Six Hours in Patients With Congestive Heart Failure, Heart Rate <70 Beats per Minute and Fluid Overload.
 
Principal Investigator: Paolo C. Colombo  
Start date: 06/16/2008
End date: 10/31/2009
to request information from Principal Investigator.
   Top of page
Perseus Trial - **STUDY MANAGER** Perseus Trial: A Prospective Evaluation in a Non-Randomized Trial of the Safety and Efficacy of the Use of the TAXUS[r] ElementTM Paclitaxel-Eluting Coronary Stent System for the Treatment
 
Principal Investigator: Jeffrey W. Moses  
Start date: 01/28/2008
End date: 08/31/2013
to request information from Principal Investigator.
   Top of page
Perseus Workhorse Trial - **STUDY MANAGER** Perseus WorkhorseTrial: A Prospective Evaluation in a Non-Randomized of the Safety and Efficacy of the Use of the TAXUS (R) ElementTM Paclitaxel-Eluting Coronary Stent System for the Treatment
 
Principal Investigator: Jeffrey W. Moses  
Start date: 01/28/2008
End date: 08/31/2013
to request information from Principal Investigator.
   Top of page
Power Disc-15 - Comparison of Safety and Inhalation Times of Ventavis (iloprost) Inhalation Solution Delivered by I-Neb Utilizing Power Disc-6 and Power Disc-15
 
Principal Investigator: Evelyn M Horn  
Start date: 06/19/2007
End date: 12/31/2009
to request information from Principal Investigator.
   Top of page
Protect II (IMPELLA) - **STUDY MANAGER** PROTECT II: A Prospective, multi-center randomized controlled trial of the IMPELLA® RECOVER® LP 2.5 System versus Intra Aortic Balloon Pump (IABP) in Patients Undergoing Non-Emergent High Risk PCI
 
Principal Investigator: Michael Collins  
Start date: 04/10/2008
End date: 10/31/2009
to request information from Principal Investigator.
   Top of page
RED-HF Trial - Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction
 
Principal Investigator: Donna Mancini  
Website: NETWORK
Start date: 11/06/2006
End date: 05/31/2010
to request information from Principal Investigator.
   Top of page
REVERSE - Resynchronization reverses remodeling in systolic left ventricular dysfunction study, REVERSE
 
Principal Investigator: Evelyn M Horn  
Start date: 02/03/2006
End date: 12/31/2011
to request information from Principal Investigator.
   Top of page
RIDE - The Impact of Cardiac Resynchronization Therapy Optimization on Indices of Mechanical Dyssynchrony during Exercise.
 
Principal Investigator: Fredrick A Ehlert  
Start date: 04/22/2008
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
RIGHT - Rhythm ID going head to head Trial
 
Principal Investigator: Jose Dizon  
Start date: 03/30/2006
End date: 09/30/2009
to request information from Principal Investigator.
   Top of page
Randomized Double blind placebo controlled parallel group trial to assess the efficacy and safety of Omacor for the prevention of recurrent symptomatic Atrial fibrillation
 
Principal Investigator: James A. Reiffel  
Start date: 02/13/2007
End date: 08/31/2011
to request information from Principal Investigator.
   Top of page
Scoring Balloon Catheter - **STUDY MANAGER** AngioSculpt bifurcation trial: AngioSculpt scoring balloon catheter coronary bifurcation study protocol
 
Principal Investigator: Jeffrey W. Moses  
Start date: 06/20/2008
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
T-wave Alternans and Ischemia - T-wave Alternans During Percutaneous Coronary Interventions.
 
Principal Investigator: Jose Dizon  
Start date: 04/28/2008
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
THAOS - Global, Multi-Center, Longitudinal, Observational Survey of Patients with Documented Transthyretin (TTR) Mutations or Wild-Type TTR Amyloidosis.
 
Principal Investigator: Matthew Maurer  
Start date: 12/04/2007
End date: 06/30/2018
to request information from Principal Investigator.
   Top of page
THAOS Sub-Study - Sub Study: TRANSTHYRETIN-ASSOCIATED AMYLOIDOSES OUTCOMES SURVEY (THAOS)-Optional Blood Sample Collection Sub-Study
 
Principal Investigator: Matthew Maurer  
Start date: 05/16/2008
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
TOPCAT - Treatment of Preserved Cardiac function heart failure with an Aldosterone antagonist
 
Principal Investigator: Matthew Maurer  
Start date: 03/23/2007
End date: 06/30/2010
to request information from Principal Investigator.
   Top of page
Tailored Treatment of Permanent Atrial Fibrillation using the Ablation Frontiers Cardiac Ablation System
 
Principal Investigator: Hasan Garan  
Start date: 04/23/2008
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
USE-BNP - Utilizing, Studying, Evaluating BNP for Monitoring in Patients with Heart Failure (USE-BNP).
 
Principal Investigator: Susan Restaino  
Start date: 06/24/2008
End date: 12/31/2010
to request information from Principal Investigator.
   Top of page
VIBRANT - GORE VIABAHN ENDOPROSTHESIS VS. BARE NITINOL STENT IN THE TREATMENT OF LONG LESION SUPERFICIAL FEMORAL ARTERY OCCLUSIVE DISEASE
 
Principal Investigator: William Gray  
Start date: 05/31/2006
End date: 11/30/2010
to request information from Principal Investigator.
   Top of page
ZoMAXX - **STUDY MANAGER** The ZoMAXX II trial: Randomized, controlled trial to evaluate the safety and efficacy of the ZoMaxx des system as compared to the TAXUS Express 2 DES in de novo coronary artery lesions
 
Principal Investigator: Martin Leon  
Start date: 01/14/2005
End date: 07/31/2012
to request information from Principal Investigator.
   Top of page


Department :Medicine
Division : Digestive & Liver Diseases
Cryospray Study - Prospective, multi-center, longitudinal cohort study of Cryospray Ablation of low grade or high grade dysplasia within Barrett's esophagus (LCD Dysplasia).
 
Principal Investigator: Charles J. Lightdale  
Start date: 10/30/2008
End date: 04/30/2011
to request information from Principal Investigator.
   Top of page
Phase IIb, Randomized, Double-Blind, Placebo Controlled Study for the Treatment of Active Celiac Disease with AT-1001.
 
Principal Investigator: Peter Green  
Start date: 01/29/2009
End date: 07/31/2010
to request information from Principal Investigator.
   Top of page
SpyGlass Retro - MultiSite, Retrospective Chart Review of Cholangioscopic Procedures using the SpyGlass(TM) Direct Visualization System
 
Principal Investigator: Peter Stevens  
Start date: 04/22/2008
End date: 10/31/2013
to request information from Principal Investigator.
   Top of page
Study of the Effect of Varying Biopsy Forceps Size on Adequacy of Tissue Acquisition in Barrett's Esophagus
 
Principal Investigator: Charles J. Lightdale  
Start date: 03/31/2008
End date: 09/30/2009
to request information from Principal Investigator.
   Top of page


Department :Medicine
Division : Endocrinology
24-Week, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of PPM-204 in Subjects With Type 2 Diabetes
 
Principal Investigator: Daniel S. Donovan, Jr.  
Start date: 05/23/2007
End date: 11/30/2009
to request information from Principal Investigator.
   Top of page
ACROSTUDY - ACROSTUDY Multicenter, Post-Marketing Surveillance study of Somavert Therapy in Patients with Acromegaly in the US and Europe
 
Principal Investigator: Pamela Freda  
Start date: 05/02/2006
End date: 11/30/2011
to request information from Principal Investigator.
   Top of page
AIM-HIGH - ATHEROTHROMBOSIS INTERVENTION in METABOLIC SYNDROME with Low HDL/HIGH TRIGLYCERIDE and IMPACT ON GLOBAL HEALTH OUTCOMES
 
Principal Investigator: Daniel S. Donovan, Jr.  
Start date: 05/15/2006
End date: 11/30/2010
to request information from Principal Investigator.
   Top of page
AVD111179 - 52 week randomized, double-blind, multicenter, mechanistic study with a 24 week open-label follow-up to evaluate the effect of AVANDIA on bone in postmenopausal women with type 2 diabetes mellitus
 
Principal Investigator: Daniel S. Donovan, Jr.  
Start date: 12/15/2008
End date: 02/28/2012
to request information from Principal Investigator.
   Top of page
Amylin Protocol - Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Long-Acting Release to Those of Sitagliptin and Pioglitazone in Subjects with Type 2 Diabetes Mellitus Tre
 
Principal Investigator: Daniel S. Donovan, Jr.  
Start date: 03/10/2008
End date: 09/30/2010
to request information from Principal Investigator.
   Top of page
Assessment of Cardiovascular Risk Markers in GH Deficient Patients with Non-secreting Pituitary Adenomas. Abbreviated Title: Cardiovascular Risk Markers in GH Deficiency
 
Principal Investigator: Pamela Freda  
Start date: 05/05/2008
End date: 11/30/2010
to request information from Principal Investigator.
   Top of page
Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors in Adult Patients with Growth Hormone Deficiency. Abbreviated Title:
 
Principal Investigator: Pamela Freda  
Start date: 04/28/2008
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
ELIXIR Study - Rapid onset and short duration Insulin Secretagogue, Mitiglinide, in combination with Metformin versus Metformin alone in patients with Type 2 Diabetes Mellitus: A randomized, doubleblind, placebo controlled trial for 6 months.
 
Principal Investigator: Daniel S. Donovan, Jr.  
Start date: 02/05/2008
End date: 08/31/2010
to request information from Principal Investigator.
   Top of page
Effects of Leptin Administration on Body Weight and Neuroendocrine Function in Weight-Reduced Individuals After Roux-en-Y Gastric Bypass Surgery. (Leptin After Gastric Bypass)
 
Principal Investigator: Judith Korner  
Start date: 01/04/2008
End date: 07/31/2010
to request information from Principal Investigator.
   Top of page
HypoCCS - The Global Hypopituitary Control and Complications Study
 
Principal Investigator: Pamela Freda  
Start date: 08/24/2006
End date: 02/28/2012
to request information from Principal Investigator.
   Top of page
IMMPRESS - Phase 3, Multi-Center, Open-Label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Mild Obstructive Pulmonary Disease Over a 12-Month Treatment Period with a
 
Principal Investigator: Daniel S. Donovan, Jr.  
Start date: 12/15/2008
End date: 06/30/2012
to request information from Principal Investigator.
   Top of page
IOOV - The Durability of Twice-Daily Insulin Lispro Low Mixture Compared to Once-Daily Insulin Glargine when added to Existing Oral Therapy in Patients with Type 2 Diabetes and Inadequate Glycemic Control
 
Principal Investigator: Daniel S. Donovan, Jr.  
Start date: 04/06/2006
End date: 10/31/2009
to request information from Principal Investigator.
   Top of page
IOP Forteo - Teriparatide For the Treatment of Idiopathic Osteoporosis in Premenopausal Women.
 
Principal Investigator: Elizabeth Shane  
Start date: 06/24/2008
End date: 03/31/2012
to request information from Principal Investigator.
   Top of page
MK-0431A - Phase III Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of MK-0431 in Patients with Type 2 Diabetes Mellitus
 
Principal Investigator: Daniel S. Donovan, Jr.  
Start date: 04/30/2008
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
Multi Center, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment with Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women with Low Bone Mineral Density
 
Principal Investigator: Elizabeth Shane  
Start date: 07/18/2006
End date: 01/31/2010
to request information from Principal Investigator.
   Top of page
Multi-center, open label study to assess the ability of subjects with acromegaly, or their partners, to administer Somatuline Autogel
 
Principal Investigator: Pamela Freda  
Start date: 04/17/2007
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
Multicenter, Randomized, Blinded Study to Assess Safety and Efficacy of Pasireotide LAR vs Octreotide LAR in patients with Active Acromegaly
 
Principal Investigator: Pamela Freda  
Start date: 02/25/2008
End date: 08/31/2011
to request information from Principal Investigator.
   Top of page
ONJ Markers - Biomarkers for bisphosphonate-associated osteonecrosis of the jaw in patients with breast cancer: a cross-sectional case control study
 
Principal Investigator: John P. Bilezikian  
Start date: 04/09/2007
End date: 10/31/2009
to request information from Principal Investigator.
   Top of page
ORIGIN - Outcome Reduction with Initial Glargine Intervention
 
Principal Investigator: Susana Ebner  
Start date: 06/30/2004
End date: 10/08/2009
to request information from Principal Investigator.
   Top of page
ORIGIN Trial - MC, International, Randomized, 2x2 Factorial design study to evaluate the effects of Lantus (Insulin Glargine) Vs Standard Care and of Omega-3 Fatty Acids Vs Placebo, in Reducing Cardiovascular Morbidity and...., IGT Early Type 2 Diabetes M
 
Principal Investigator: Daniel S. Donovan, Jr.  
Start date: 05/20/2005
End date: 11/30/2010
to request information from Principal Investigator.
   Top of page
Once-Daily Dose-Ranging Study of GSK189075 Versus Placebo In Treatment of Type 2 Diabetes Mellitus In Treatment-Naive Subjects
 
Principal Investigator: Daniel S. Donovan, Jr.  
Start date: 09/25/2007
End date: 01/31/2010
to request information from Principal Investigator.
   Top of page
Randomized, double-blind study to assess the safety and efficacy of different dose levels of pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recurrent Cushing's disease.
 
Principal Investigator: Pamela Freda  
Start date: 04/19/2007
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
Substudy - A 52 week randomized, dobule-blind, multicenter, mechanistic study with a 24 week open-label follow-up to evaluate the effect of AVANDIA on bone in postmenopausal women with type 2 diabetes mellitus
 
Principal Investigator: John P. Bilezikian  
Start date: 11/17/2008
End date: 05/30/2012
to request information from Principal Investigator.
   Top of page
The Effects of PTH on the Skeleton in Hypoparathyroidism
 
Principal Investigator: John P. Bilezikian  
Start date: 04/27/2007
End date: 10/31/2009
to request information from Principal Investigator.
   Top of page
VIAJECT 06J - An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAJECT™ and Regular Human Insulin in Patients with Type 1 Diabetes Mellitus
 
Principal Investigator: Daniel S. Donovan, Jr.  
Start date: 11/26/2007
End date: 05/31/2010
to request information from Principal Investigator.
   Top of page
VIAJECT 08J - An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAJECT™ and Regular Human Insulin in Patients with Type 2 Diabetes Mellitus
 
Principal Investigator: Daniel S. Donovan, Jr.  
Start date: 11/26/2007
End date: 05/31/2010
to request information from Principal Investigator.
   Top of page
Zolendronic Acid - Zoledronic Acid vs Alendronate for prevention of Bone Loss after Organ Transplantation
 
Principal Investigator: Elizabeth Shane  
Start date: 06/02/2005
End date: 12/31/2009
to request information from Principal Investigator.
   Top of page


Department :Medicine
Division : General Medicine
Diagnostic Labelling: Effect on White coat Hypertension
 
Principal Investigator: Tanya Goyal  
Start date: 07/15/2007
End date: 05/31/2011
to request information from Principal Investigator.
   Top of page
PA-04-107 - Improving Med Adherence in Post-ACS Patients: Phase IB Dose-Finding RCT
 
Principal Investigator: Karina W. Davidson  
Start date: 09/01/2006
End date: 07/31/2011
to request information from Principal Investigator.
   Top of page
RCT of Controlled Breathing Effects on Ambulatory BP
 
Principal Investigator: William Gerin  
Start date: 09/01/2007
End date: 08/31/2012
to request information from Principal Investigator.
   Top of page
Rheos Pivotal Trial - Rheos Baroreflex Hypertension Therapy System CONSULTING AGREEMENT
 
Principal Investigator: Thomas Pickering  
Start date: 04/12/2008
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
SPIRATE - RESPERATE hypertension randomized controlled trial
 
Principal Investigator: Lynn Clemow  
Start date: 07/01/2008
End date: 06/30/2013
to request information from Principal Investigator.
   Top of page


Department :Medicine
Division : Hematology and Oncology
**STUDY MANAGER** A Phase II Multicenter, Open Label, Two-Stage Design Study Evaluating E7389 in Patients with Hormone Refractory Prostate Cancer with Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy.
 
Principal Investigator: Daniel P. Petrylak  
Start date: 03/15/2006
End date: 09/30/2011
to request information from Principal Investigator.
   Top of page
**STUDY MANAGER** Baxter TRAC-R: A 12-month follow-up double-blind, prospective, randomized, placebo-controlled study to dtermine the tolerability, efficacy, safety, and dose range of intramyocardial injections of G-CSF mobilized Auto-CD34...
 
Principal Investigator: William Sherman  
Start date: 09/10/2008
End date: 09/30/2009
to request information from Principal Investigator.
   Top of page
...Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination with Rituximad Compared to a Defined Invetigator's Choice Therapy in Subjects with Relapsed or Refractory, CD22-Positive, Follicular B-Cell Non Hodgkin's Lymphoma
 
Principal Investigator: Owen O'Connor  
Start date: 05/27/2008
End date: 11/30/2013
to request information from Principal Investigator.
   Top of page
263 Trial - ABT-263: A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Lymphoid Malignancies
 
Principal Investigator: Owen O'Connor  
Start date: 04/27/2007
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
A6181030 - Phase II, Open-Label, Non-Randomized Trial of Sunitinib in Certain Subtypes of Soft Tissue Sarcomas
 
Principal Investigator: Robert Taub  
Start date: 04/17/2007
End date: 10/31/2012
to request information from Principal Investigator.
   Top of page
AMN107 Compassionate Study - Compassionate Use of AMN107 in a Single Patient With Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) Patient - JD
 
Principal Investigator: Robert Taub  
Start date: 11/08/2007
End date: 05/30/2011
to request information from Principal Investigator.
   Top of page
AMN107 Compassionate Study - Compassionate Use of AMN107 in a Single Patient With Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) Patient - JG
 
Principal Investigator: Robert Taub  
Start date: 11/08/2007
End date: 05/30/2013
to request information from Principal Investigator.
   Top of page
AMN107 Compassionate Study - Compassionate Use of AMN107 in a Single Patient With Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST). PATIENT NB
 
Principal Investigator: Robert Taub  
Start date: 11/08/2007
End date: 05/30/2011
to request information from Principal Investigator.
   Top of page
AN OPEN-LABEL SUNITINIB MALATE (SU011248) CONTINUATION PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PRIOR SUNITINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO HAVE THE POTENTIAL TO BENEFIT FROM SUNITINIB TREATMENTContinuation GIST Trial
 
Principal Investigator: Robert Taub  
Start date: 11/02/2007
End date: 05/31/2011
to request information from Principal Investigator.
   Top of page
AZD6244 - Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 vs. capecitabine (Xeloda™) in Patients with Advanced or Metastatic Pancreatic Cancer, who have Failed First LIne gemcitabine Therapy (Gemzar)
 
Principal Investigator: Robert Fine  
Start date: 10/18/2006
End date: 04/30/2010
to request information from Principal Investigator.
   Top of page
Acupuncture for joint pain induced by aromatose inhibitors
 
Principal Investigator: Katherine Crew  
Start date: 01/01/2006
End date: 12/31/2009
to request information from Principal Investigator.
   Top of page
C15002 - An Open-Label, Dose Escalation, Phase 1 Study of MLN4924, a Novel Inhibitor of Nedd8-Activating Enzyme, in Adult Patients with Lymphoma or Multiple Myeloma
 
Principal Investigator: Owen O'Connor  
Start date: 07/30/2008
End date: 09/30/2012
to request information from Principal Investigator.
   Top of page
CA183001 - Phase II study of Intravenous Vinflunine in patients with locally advanced or metastatic transitional cell carcinoma of the urothelium (Study No. CA183001)
 
Principal Investigator: Daniel P. Petrylak  
Start date: 11/29/2005
End date: 05/30/2011
to request information from Principal Investigator.
   Top of page
CAFE - The CAFE Study - Cancer Patient Fracture Evaluation
 
Principal Investigator: Gregory Mears  
Start date: 03/13/2006
End date: 09/30/2011
to request information from Principal Investigator.
   Top of page
COMPASSIONATE USE - COMPASSIONATE USE PROTOCOL FOR AMD3100 TO MOBILIZE PERIPHERAL BLOOD STEM CELLS FOR COLLECTION AND TRANSPLANTATION
 
Principal Investigator: Ajai Chari  
Start date: 11/27/2007
End date: 05/31/2011
to request information from Principal Investigator.
   Top of page
CRAD001N2201 - CONTRACT-"An open label, single arm, phase II study of RAD001 in patients with refractory mantle cell lymphoma"
 
Principal Investigator: Owen O'Connor  
Start date: 07/07/2008
End date: 10/01/2011
to request information from Principal Investigator.
   Top of page
Cell-Genesys/GC1940/A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients with Metastatic Hormone-Refractory Prostate Cancer who are Chemotherapy-Naïve
 
Principal Investigator: Daniel P. Petrylak  
Start date: 05/11/2006
End date: 11/30/2010
to request information from Principal Investigator.
   Top of page
Combination Chemotherapy Trial of Gemtuzumab Ogozamicin with Escalating Dose of Mitoxantrone in Patients with AML and High Risk MDS0
 
Principal Investigator: Gwen Nichols  
Start date: 06/18/2002
End date: 06/30/2010
to request information from Principal Investigator.
   Top of page
D9902B - Randomized, Double Blind, Placebo-Controlled Phase 3 Trial of Immunotherapy with Autologous Antigen presenting Cells Loaded with PA2024 (Provenge, APC8015) in Men with Metastatic Androgen Independent Prostatic Adenocarcin
 
Principal Investigator: Daniel P. Petrylak  
Start date: 01/18/2007
End date: 07/31/2013
to request information from Principal Investigator.
   Top of page
DFCI ALL Adult Consortium Protocol
 
Principal Investigator: Jasmine M. Zain  
Start date: 09/22/2008
End date: 04/28/2013
to request information from Principal Investigator.
   Top of page
EFC6668 - Work Order No. 2-Randomized study of Larotaxel + cisplatin (LC) vs. gemcitabine + cisplatin (GC) in the first line treatment of locally advanced/ metastatic urothelial tract and bladder cancer
 
Principal Investigator: Daniel P. Petrylak  
Start date: 05/29/2008
End date: 02/01/2013
to request information from Principal Investigator.
   Top of page
EXPANDED ACCESS - Expanded access study of plerixafor and G-CSF for the mobilization and collection of peripheral blood stem cell for autologous stem cell transplantation in plants with non-hodkin's lymphoma, hodgkin's disease or multiple myeloma
 
Principal Investigator: Jasmine M. Zain  
Start date: 11/18/2008
End date: 05/30/2012
to request information from Principal Investigator.
   Top of page
EXPLORE - Examination of PNH by Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes
 
Principal Investigator: Michael J Flamm  
Start date: 04/06/2007
End date: 10/31/2011
to request information from Principal Investigator.
   Top of page
Enzastaurin - Phase 2 Trial of Oral Enzastaurin in Prostate Cancer Patients who have Rising PSA (1) During Hormonal Manipulation, and (2) after First-Line Cytotoxic Chemotherapy
 
Principal Investigator: Daniel P. Petrylak  
Start date: 04/17/2007
End date: 10/31/2012
to request information from Principal Investigator.
   Top of page
Extended 39-week Study of PSMA ADC Following the Initial 12-week Dose-Escalation Study in Subjects with Progressive, Castration-Resistant, Metastatic Prostate Cancer.
 
Principal Investigator: Daniel P. Petrylak  
Start date: 09/23/2008
End date: 04/15/2011
to request information from Principal Investigator.
   Top of page
GIST - PHASE IIIB, RANDOMIZED, ACTIVE CONTROLLED OPEN-LABEL STUDY OF SUNITINIB (SUTENT®) 37.5 MG DAILY VS IMATINIB]MESYLATE 800 MG DAILY IN THE TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMORS (GIST) WHO HAVE HAD PROGRESSIVE DISEASE WHILE ON 400
 
Principal Investigator: Robert Taub  
Start date: 10/04/2007
End date: 05/31/2011
to request information from Principal Investigator.
   Top of page
IRUSANAS0090 - Phase II Study of Glucosamine with Chondroitin on Joint Symptoms Induced by Aromatase Inhibitors in Breast Cancer Patients.
 
Principal Investigator: Dawn L Hershman  
Start date: 04/10/2008
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
Multicenter, Open-Label Single- Arm Study of Yondelis (trabectedin) for Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment
 
Principal Investigator: Robert Taub  
Start date: 10/04/2006
End date: 04/30/2010
to request information from Principal Investigator.
   Top of page
Multicenter, randomized, 2-blind, ph3 study of Sunitib plu prednisone versus prednisone in patients with progressive metastatic hormone-refractory prostate cancer after failure of a Docetaxel-based chemotherapy regimen
 
Principal Investigator: Daniel P. Petrylak  
Start date: 11/25/2008
End date: 12/31/2012
to request information from Principal Investigator.
   Top of page
PB01 - An Open Label, Single Arm Trial of Immunotherapy With Autologous Antigen Presenting Cells Loaded with PA2024 (APC8015F) for Men with Objective Disease Progression on Protocol D9902 Part B
 
Principal Investigator: Daniel P. Petrylak  
Start date: 01/24/2007
End date: 07/31/2011
to request information from Principal Investigator.
   Top of page
PHASE I/II STUDY OF 10-PROPARGYL-10-DEAZAAMINOPTERIN (PDX) IN RELAPSED OR REFRACTORY AGGRESSIVE LYMPHOPROLIFERATIVE MALIGNANCIES
 
Principal Investigator: Owen O'Connor  
Start date: 04/30/2007
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
PILL-2 - Phase I/II Study of the Novel Proteasome Inhibitor Bortezomib in Combination with Rituximab, Cyclophosphamide and Prednisone in Patients with Relapsed/Refractory Indolent B-cell Lymphoproliferative Disorders and mantle Cell Lymphoma (MCL)
 
Principal Investigator: Owen O'Connor  
Start date: 09/29/2007
End date: 03/31/2011
to request information from Principal Investigator.
   Top of page
PSMA ADC 1301: A Phase I Dose-Escalation Study of PSMA ADC in Subjects with Progressive Castration-Resistant Metastatic Prostate Cancer Dose.
 
Principal Investigator: Daniel P. Petrylak  
Start date: 09/23/2008
End date: 04/15/2011
to request information from Principal Investigator.
   Top of page
PX-171-002 - Phase 1 Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients with Hematological Malignancies: Four Week Cycle (PX-171-002)
 
Principal Investigator: Owen O'Connor  
Start date: 03/10/2008
End date: 09/30/2009
to request information from Principal Investigator.
   Top of page
Pancreatic Cancer Serum and DNA Repository
 
Principal Investigator: Robert Fine  
Start date: 08/14/2006
End date: 02/28/2011
to request information from Principal Investigator.
   Top of page
Phase 1 Open-Label Study Evaluating Atrasentan (ABT-627) in combination with Docetaxel and Estramustine in the Treatment of Hormone Refractory Prostate Cancer
 
Principal Investigator: Daniel P. Petrylak  
Start date: 04/08/2005
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
Phase 1/2a Open-label Study of Sequential Pralatrexate and Gemcitabine with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Lymphoproliferative Malignancies
 
Principal Investigator: Owen O'Connor  
Start date: 05/03/2007
End date: 11/30/2010
to request information from Principal Investigator.
   Top of page
Phase 2 Multicenter, Open-labek Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination with Mitoxantrone versus Mitoxantrone in Subjects with Metastatic Hormone-Refactory Prostate Cancer (HRPC
 
Principal Investigator: Daniel P. Petrylak  
Start date: 06/14/2007
End date: 12/31/2009
to request information from Principal Investigator.
   Top of page
Phase 2 Study of Cisplatin + Pemetrexed + Bevacizumab as First-Line Therapy in Patients with Advanced Non-Squamous, Non-Small Cell Lung Carcinoma
 
Principal Investigator: Mark Stoopler  
Start date: 06/11/2007
End date: 12/31/2011
to request information from Principal Investigator.
   Top of page
Phase 2, Single-Arm, Opoen Label, Multiple center study of CP-751 ,871 in combination with Docetaxel and Prednisone in Patients with Progressive hormone refractory prostate cancer
 
Principal Investigator: Daniel P. Petrylak  
Start date: 07/31/2006
End date: 02/28/2012
to request information from Principal Investigator.
   Top of page
Phase 2, multicenter, randomized study of IMC-A12 or IMC-1121B plus mitoxantrone and prednisone in metastatic androgen-independent prostate cancer
 
Principal Investigator: Daniel P. Petrylak  
Start date: 10/16/2008
End date: 04/30/2014
to request information from Principal Investigator.
   Top of page
Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) plus Bortezomib Compared to Bortezomib Alone in Patients with Multiple Myeloma in First Relapse.
 
Principal Investigator: Jasmine M. Zain  
Start date: 02/04/2008
End date: 08/31/2013
to request information from Principal Investigator.
   Top of page
Phase 3 Randomized, PC, DB, study of Oral CCI-779 Admin in combination with Letrozole vs. Letrozole Alone as First Line Hormonal Therapy in Postmenopausal Women w/ Locally Advanced or Metastatic Breast Cancer
 
Principal Investigator: Dawn L Hershman  
Start date: 06/30/2004
End date: 10/06/2011
to request information from Principal Investigator.
   Top of page
Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide In Patients With Unresectable Or Metastatic Soft Tissue Sarcoma or Malignant Mesothelioma
 
Principal Investigator: Robert Taub  
Start date: 10/31/2007
End date: 04/30/2013
to request information from Principal Investigator.
   Top of page
Phase I Open Label Study of Noscapine (CB3304 ) in Patients with Relapsed or Refractory Multiple Myeloma
 
Principal Investigator: Jasmine M. Zain  
Start date: 01/15/2008
End date: 08/31/2010
to request information from Principal Investigator.
   Top of page
Phase I Open-Label, Dose Escalation Study to Determine the Maximum Tolerated Dose and to Evaluate the Safety Profile of Lenalidomide (Revlimid CC-5013) with Every Three Week Docetaxel (Taxotere) in Subjects with Androgen Independent Prostate
 
Principal Investigator: Daniel P. Petrylak  
Start date: 08/30/2005
End date: 02/28/2011
to request information from Principal Investigator.
   Top of page
Phase I Study of Vorinostat in Combination with Niacinamide, and Etoposide for the Treatment of Patients with Relapsed and Refractory Lymphoid Malignancies.
 
Principal Investigator: Owen O'Connor  
Start date: 12/17/2007
End date: 10/31/2012
to request information from Principal Investigator.
   Top of page
Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients with Hematological Malignancies: Two Week Cycle
 
Principal Investigator: Owen O'Connor  
Start date: 04/26/2007
End date: 10/31/2009
to request information from Principal Investigator.
   Top of page
Phase I Trial of Alimta (Pemetrexed) plus Taxotere (Doxetaxel) in Advanced Malignancies and Phase II trial of ALimta plus Taxotere in Adnrogen independent metastatic prostate cancer
 
Principal Investigator: Daniel P. Petrylak  
Start date: 05/31/2005
End date: 11/30/2011
to request information from Principal Investigator.
   Top of page
Phase I-II Study to Determine the Safety and Pharmacokinetics of Intravenous Administration of SB-743921 on Days 1 and 15 of a 28 Day Cycle in Patients with Non-Hodgkin’s Lymphoma
 
Principal Investigator: Owen O'Connor  
Start date: 04/20/2007
End date: 10/30/2009
to request information from Principal Investigator.
   Top of page
Phase I/II Trial of Docetaxel, Prednisone, Bevacizumab and Erlotinib in Hormone Refractory Prostate Cancer
 
Principal Investigator: Daniel P. Petrylak  
Start date: 07/26/2006
End date: 01/31/2011
to request information from Principal Investigator.
   Top of page
Phase I/II study of HKI-272 in combination with vinorelbine in subjects with solid tumors and metastatic breast cancer wyth: HKI272
 
Principal Investigator: Dawn L Hershman  
Start date: 03/17/2008
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
Phase II Clinical Trial to Determine if Polyphenon E Inhibits c-Met Signaling and Activation of Pathways Contributing to Breast Cancer Progression
 
Principal Investigator: Katherine Crew  
Start date: 08/09/2007
End date: 04/30/2010
to request information from Principal Investigator.
   Top of page
Phase II Study of Capecitabine and Temozolomide for Progressive, Differentiated, Metastatic Neuroendocrine Cancers
 
Principal Investigator: Robert Fine  
Start date: 07/11/2006
End date: 01/31/2012
to request information from Principal Investigator.
   Top of page
Phase II Study of GW786034 using a Randomized Discontinuation Design in Subjects with Locally Recurrent or Metastatic Clear-Cell Renal Cell Carcinoma
 
Principal Investigator: Daniel P. Petrylak  
Start date: 04/17/2006
End date: 10/31/2009
to request information from Principal Investigator.
   Top of page
Phase II study of milataxel (TL139) administered orally in patients with malignant mesothelioma phase II TL139 in patients with mesotherlioma
 
Principal Investigator: Robert Taub  
Start date: 10/16/2008
End date: 04/30/2013
to request information from Principal Investigator.
   Top of page
Phase II, Multicenter, Open-Label Trial Evaluating the Activity and Tolerability of romidepsin (depsipeptide, FK228) in Progressive or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy.
 
Principal Investigator: Jasmine M. Zain  
Start date: 04/15/2008
End date: 04/15/2013
to request information from Principal Investigator.
   Top of page
Phase II, Randomized, Open-Label, Three-Arm, MC study of MEDI-522, A Humanized Monoclonal Antibody Directed Against teh Human Alpha V Beta 3 Integrin, In Combination with Weekly Docetaxel +/- Low-Dose Estramustine and Zoledronic Acid In the Treatment
 
Principal Investigator: Daniel P. Petrylak  
Start date: 01/19/2005
End date: 07/30/2010
to request information from Principal Investigator.
   Top of page
Phase Ib Open-Label, Two-Arm, Dose-Finding Study of E7389 in Combination with Carboplatin in Patients with Solid Tumors
 
Principal Investigator: Daniel P. Petrylak  
Start date: 10/02/2006
End date: 04/30/2012
to request information from Principal Investigator.
   Top of page
Poly E MTA - Phase II Clinical Trial to Determine if Polyphenon E Inhibits c-met Signaling and Activation of Pathways Contributing to Breast Cancer Progression
 
Principal Investigator: Katherine Crew  
Start date: 07/18/2007
End date: 01/31/2010
to request information from Principal Investigator.
   Top of page
Pralatrexate - Phase 1, Open-label Study of Pralatrexate with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Cutaneous T-cell Lymphoma
 
Principal Investigator: Jasmine M. Zain  
Start date: 07/13/2007
End date: 01/31/2011
to request information from Principal Investigator.
   Top of page
Randomized Phase II study of docetaxel +/- ZD6474 (Zactima) in Metastatic Transitional Cell Carcinoma
 
Principal Investigator: Daniel P. Petrylak  
Start date: 09/06/2007
End date: 03/31/2013
to request information from Principal Investigator.
   Top of page
Randomized double-blind phase III study of RAD001 10 mg/d plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine tumor (NET)
 
Principal Investigator: Robert Fine  
Start date: 08/27/2008
End date: 09/30/2010
to request information from Principal Investigator.
   Top of page
Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging bone Metastasis-Free Survival in Men with Hormone Refractory Prostate Cancer
 
Principal Investigator: Daniel P. Petrylak  
Start date: 01/14/2008
End date: 10/31/2011
to request information from Principal Investigator.
   Top of page
Randomized, multicenter, single blind study in men with metastatic androgen independent prostate cancer to evaluate sipuleucel-T manufactured with different concentations of PA2024 antigen
 
Principal Investigator: Daniel P. Petrylak  
Start date: 11/03/2008
End date: 05/13/2013
to request information from Principal Investigator.
   Top of page
SKI-606 - Phase 2, randomized, OL studyof Bosutinib administered in combo with exemestaine vs. exemestane alone as 2 line therapy in postmenopausal women with locally advanced or metastatic er+pgR+/erb2 Breast cancer
 
Principal Investigator: Dawn L Hershman  
Start date: 02/04/2009
End date: 08/30/2014
to request information from Principal Investigator.
   Top of page
SUCCEED - Pivotal Trial to Determine the Efficacy and Safety of AP23573 when Administered as Maintenance Therapy to Patients with Metastatic Soft-Tissue or Bone Sarcomas.
 
Principal Investigator: Robert Taub  
Start date: 03/15/2008
End date: 03/15/2012
to request information from Principal Investigator.
   Top of page
Two-arm, non-randomized, multicenter, phase 2 study of VELCADE (bortezomib) in combination with rituximab, cyclophosphamide, and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed follicular lymphoma
 
Principal Investigator: Owen O'Connor  
Start date: 09/26/2008
End date: 02/28/2014
to request information from Principal Investigator.
   Top of page
VELCADE - 2 Stage, open label, phase 2 study of Velcade plus Eloxatin in previously treated patients with malignant pleural or peritoneal mesotheliona
 
Principal Investigator: Robert Taub  
Start date: 03/06/2009
End date: 09/30/2013
to request information from Principal Investigator.
   Top of page
VENICE - Multicenter, Randomized, Double-Blind Study comparing the Efficacy and Safety of Flibercept Versus Placebo Administered Every 3 Weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate Cancer
 
Principal Investigator: Daniel P. Petrylak  
Start date: 01/22/2008
End date: 08/31/2013
to request information from Principal Investigator.
   Top of page
VINCENT - Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients who are Ineligible to Receive
 
Principal Investigator: Daniel P. Petrylak  
Start date: 04/23/2007
End date: 10/31/2014
to request information from Principal Investigator.
   Top of page
Wyeth HKI-272 (2) - Phase 1/2 Study of HKI-272 in Combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer.
 
Principal Investigator: Dawn L Hershman  
Start date: 07/25/2007
End date: 03/31/2011
to request information from Principal Investigator.
   Top of page
entitled A Multi-center Phase 2 Open-label Study of (RS)-10-Propargyl-10-Deazaaminopterin (pralatrexate) with Vitamin B12 and Folic Acid Supplementation in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma, Protocol No. PDX-008
 
Principal Investigator: Owen O'Connor  
Start date: 03/21/2007
End date: 09/30/2009
to request information from Principal Investigator.
   Top of page


Department :Medicine
Division : Infectious Diseases
A4001027 HIV1 - MC, RZd, Db, PC trial of a novel CCR5 antagonist , UK 427857 in combination with optimized background therapy vs. optimized background therapy alone for the treatment of antitroviral experienced HIV1 infected subjects
 
Principal Investigator: Peter Gordon  
Start date: 08/27/2008
End date: 12/31/2011
to request information from Principal Investigator.
   Top of page
PARC'S - PARC'S HIV Elite Controller Study
 
Principal Investigator: Susan Aileen Olender  
Start date: 06/01/2007
End date: 12/30/2012
to request information from Principal Investigator.
   Top of page
Pfizer EAP - Pfizer HIV Expanded Access Program (EAP) protocol Number A4001050
 
Principal Investigator: Peter Gordon  
Start date: 05/21/2007
End date: 11/30/2009
to request information from Principal Investigator.
   Top of page
Raltegravir - Phase III open label single arm study to evaluate the safety. tolerability and efficacy of MK-0518/Raltegravir i a diverse cohort of HIV infected patients.
 
Principal Investigator: Michael T. Yin  
Start date: 02/25/2009
End date: 08/31/2010
to request information from Principal Investigator.
   Top of page


Department :Medicine
Division : Medical Oncology
Phase II Study of AVN944 in Combination with Gemcitabine For the Treatment of Pancreatic Cancer
 
Principal Investigator: Michael John Hall  
Website: www.avalonrx.com
Start date: 06/13/2008
End date: 11/30/2010
to request information from Principal Investigator.
   Top of page


Department :Medicine
Division : Nephrology
**STUDY MANAGER** A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel-arm Trial to Determine Long-term Safety and Efficacy of Oral Tolvaptan Tablet Regimens in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease
 
Principal Investigator: Jai Radhakrishnan  
Start date: 11/06/2007
End date: 05/30/2012
to request information from Principal Investigator.
   Top of page
**STUDY MANAGER** A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 For Prevention of Chronic Kidney Disease Progression in Patients With Moderate to Severe Chronic Kidney Disease Including Assessment
 
Principal Investigator: Leonard Stern  
Start date: 01/29/2009
End date: 06/30/2013
to request information from Principal Investigator.
   Top of page
AEB - 12-month open-label, randomized, multicenter, sequential cohort, dose finding study to evaluate the efficacy, safety and tolerability of oral AEB071 versus tacrolimus in combination with myfortic®, Simulect® and corticosteroids in de novo adult rena
 
Principal Investigator: David J. Cohen  
Start date: 01/17/2008
End date: 07/31/2010
to request information from Principal Investigator.
   Top of page
ALMS - Prospective, Rzd, Db, Act- cont, PG, MC trial to assess the efficacy and safety of mycophenolate mofetil in maintaining remission and renal functioin in subjects with lupus nephritis who underwent induction therapy with either MMF or Cyclophosphami
 
Principal Investigator: Gerald B. Appel  
Start date: 11/11/2005
End date: 05/31/2010
to request information from Principal Investigator.
   Top of page
BELONG - Randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the efficacy and safety of two doses of ocrelizumab in patients with WHO or ISN Class III or IV nephritis due to systematic lupus erythematosus
 
Principal Investigator: Gerald B. Appel  
Start date: 11/13/2008
End date: 05/31/2014
to request information from Principal Investigator.
   Top of page
Bone Histomorphometry Assessment For Dialysis Patients with Secondary Hyperparathyroidism of End Stage Renal Disease.
 
Principal Investigator: Thomas Nickolas  
Start date: 07/23/2007
End date: 01/31/2010
to request information from Principal Investigator.
   Top of page
CORAL - Cardiovascular Outcome in Renal Atherosclerotic Lesions Randomized & Multicenter Two Group Clinical Trial to Assess the Best Treatment for Patients with High Blood Pressure & Renal Artery Stenosis
 
Principal Investigator: Gerald B. Appel  
Start date: 05/17/2006
End date: 03/31/2010
to request information from Principal Investigator.
   Top of page
Collaborative study Group Trial: The Effect of Sulodexide in Overt Type 2 Diabetic Nephropathy
 
Principal Investigator: Cheryl Lynne Kunis  
Start date: 04/11/2006
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
LCP tacro 2017 - Phase 2,Open label, mc, randomized trail to demostrate the pharmacokinetics of LCP-tacro tablets 2 daily and Prograf capsules 2 day in adult de novo kindney transplant patients
 
Principal Investigator: David J. Cohen  
Start date: 11/12/2008
End date: 05/31/2014
to request information from Principal Investigator.
   Top of page
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects with ISN/RPS Class III of IV Lupus Nephritis
 
Principal Investigator: Gerald B. Appel  
Start date: 03/23/2006
End date: 12/31/2010
to request information from Principal Investigator.
   Top of page
SHPT registry - SHPT Registry- Chronic Kidney Disease Subjects on Dialysis with Secondary Hyperparathyroidism
 
Principal Investigator: Leonard Stern  
Start date: 04/22/2005
End date: 10/31/2012
to request information from Principal Investigator.
   Top of page


Department :Medicine
Division : Preventive Medicine & Nutrition
RADICHOL II - RADICHOL II: A Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of ISIS 301012 as Add-on Therapy in Heterozygous Familial Hypercholesterolemia Subjects with Coronary Artery Disease
 
Principal Investigator: Henry N. Ginsberg  
Start date: 10/14/2008
End date: 04/30/2011
to request information from Principal Investigator.
   Top of page


Department :Medicine
Division : Pulmonary Cardiology
IGIV for Lung Transplant - IGIV For Acquired Immunodeficiency in Lung Transplant Patients
 
Principal Investigator: Selim Arcasoy  
Start date: 03/31/2005
End date: 12/31/2009
to request information from Principal Investigator.
   Top of page
Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Cyclosporine Inhalation Solution (CIS) in ...
 
Principal Investigator: Selim Arcasoy  
Start date: 11/25/2008
End date: 05/31/2013
to request information from Principal Investigator.
   Top of page


Department :Medicine
Division : Pulmonary, Allergy & Critical Care Medicine
ARTEMIS - ARTEMIS: A phase 3, randomized 2-blind, placebo-controlled, mc, parallel group, event driven study to evaluate the efficacy and safety of Ambrisentan in subjects with early idiopathic pulmonary fibrosis (IPF)
 
Principal Investigator: David J. Lederer  
Start date: 01/29/2009
End date: 07/30/2013
to request information from Principal Investigator.
   Top of page
Airway Gene Expression in the Diagnosis of Lung Cancer
 
Principal Investigator: Charles Powell  
Start date: 01/12/2009
End date: 07/31/2010
to request information from Principal Investigator.
   Top of page
An Open-Label Extension Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF) Who Complete the CAPACITY Studies.
 
Principal Investigator: Nina Patel  
Start date: 07/02/2008
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
Bronchiectasis Research Registry
 
Principal Investigator: Byron Thomashow  
Start date: 10/28/2008
End date: 04/30/2014
to request information from Principal Investigator.
   Top of page
Clinical Trial of Aspirin and Simvastatin in Pulmonary Arterial Hypertension
 
Principal Investigator: Steven M. Kawut  
Start date: 03/01/2006
End date: 02/28/2011
to request information from Principal Investigator.
   Top of page
Double-blind, randomized, placebo-controlled study to evaluate the safety, pharmacokinetics, and efficacy of IMA-638 in subjects with persistent asthma
 
Principal Investigator: Emily DiMango  
Start date: 01/25/2008
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
EASE TRIAL - Randomized, Double-blind Study to Evaluate the Safety and Effectiveness of the Exhale® Drug-Eluting Stent in Homogeneous Emphysema Subjects with Severe Hyperinflation
 
Principal Investigator: Roger Maxfield  
Start date: 01/24/2007
End date: 07/31/2012
to request information from Principal Investigator.
   Top of page
TIGER - 2 - Phase 3, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Denufosol Tetrasodium Inhalation Solution in Patients with Cystic Fibrosis Lung Disease and FEV1 > 75% Predicted
 
Principal Investigator: Emily DiMango  
Start date: 05/13/2008
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
Tuberculosis Trials Consortium
 
Principal Investigator: Neil W Schluger  
Start date: 09/23/1999
End date: 09/22/2009
to request information from Principal Investigator.
   Top of page


Department :Medicine
Division : Rheumatology
ABATACEPT - Phase IIB, Multi-Center, Rzd, DB, Pc Study to Evaluate the Efficacy and Safety of Abatacept vs. Placebo on a Background of Oral Glucocorticosteroids in the Tnt of Sjts with Systemic Lupus Erythematosus and the prevention of subsequent lupus fl
 
Principal Investigator: Meggan Mackay  
Start date: 05/25/2006
End date: 11/30/2009
to request information from Principal Investigator.
   Top of page
Mechanism of action-Rituximab in SLE
 
Principal Investigator: Betty Diamond  
Start date: 01/25/2007
End date: 07/31/2010
to request information from Principal Investigator.
   Top of page
Randomized, parallel, double-blind, placebo-controlled dose regimen finding study to evaluate the safety and efficacy of TRU-015 in subjects wtih active seropositive rheumatoid arthritis on a background of methotrexate
 
Principal Investigator: Edward Dwyer  
Start date: 05/01/2008
End date: 10/30/2010
to request information from Principal Investigator.
   Top of page


Department :Neurological Surgery
Division : Epilepsy Movement
Clinical Evaluation For The Management of Patients With Single or Recurrent Major Depressive Disorder With Deep Brain Stimulation.
 
Principal Investigator: Robert R Goodman  
Start date: 04/10/2008
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page


Department :Neurological Surgery
Division : Neuro Surgeon
Multicenter Study of Non-invasive Intracranial Pressure
 
Principal Investigator: Sander E. Connolly  
Start date: 03/16/2007
End date: 09/30/2009
to request information from Principal Investigator.
   Top of page


Department :Neurological Surgery
Division : Neurooncology
Prospective Multi-Center Trial of NovoTTF-100A Compared to Best Standard of Care in Patients with Progressive or Recurrent GBM
 
Principal Investigator: Jeffrey N Bruce  
Start date: 11/17/2006
End date: 05/31/2010
to request information from Principal Investigator.
   Top of page


Department :Neurological Surgery
Division : Spine
Prospective, Multi-Center, Randomized Controlled Study to Compare the Spinal Sealant System as an Adjunct to Sutured Dural Repair with Standard of Care Methods during Spinal Surgery
 
Principal Investigator: Paul McCormick  
Start date: 05/24/2007
End date: 11/30/2009
to request information from Principal Investigator.
   Top of page
Prospective, Multi-Center, Randomized Controlled Study to comapre the Spinal Sealant System as an Adjunct to Sutured Dural Repair with Standard of Care Methods during Spinal Surgery.
 
Principal Investigator: Michael Kaiser  
Start date: 01/12/2006
End date: 12/31/2009
to request information from Principal Investigator.
   Top of page
Prospective, Randomized Clinical Investigation of the SECURE-C Cervical Artificial Disc: A Pivotal Study
 
Principal Investigator: Michael Kaiser  
Start date: 03/22/2006
End date: 09/30/2010
to request information from Principal Investigator.
   Top of page


Department :Neurology
Division : Dementia and Aging
Effect of Gamma-Secretase Inhibition on the Progression of Alzheimer’s Disease: LY450139 versus Placebo.
 
Principal Investigator: Lawrence S. Honig  
Start date: 08/14/2008
End date: 03/31/2013
to request information from Principal Investigator.
   Top of page
Elan - 301 - ELN115727-301: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of Bapineuzumab (AAB 001, ELN115727) in Patients with Mild to Moderate Alzheimer’s Disease who are Apolipoprotein
 
Principal Investigator: Lawrence S. Honig  
Start date: 04/28/2008
End date: 07/31/2011
to request information from Principal Investigator.
   Top of page
Elan 302 - ELN115727-301: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of Bapineuzumab (AAB 001, ELN115727) in Patients with Mild to Moderate Alzheimer’s Disease who are Apolipoprotein E
 
Principal Investigator: Lawrence S. Honig  
Start date: 04/28/2008
End date: 07/31/2011
to request information from Principal Investigator.
   Top of page
Open Label Study of the Effect of Daily Treatment with MPC-7869 in Subjects with Dementia of the Alzheimer's Type
 
Principal Investigator: Lawrence S. Honig  
Start date: 05/05/2007
End date: 11/30/2010
to request information from Principal Investigator.
   Top of page
Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral ELND005 (AZD-103) in Alzheimer’s Disease.
 
Principal Investigator: Lawrence S. Honig  
Start date: 04/28/2008
End date: 10/31/2013
to request information from Principal Investigator.
   Top of page


Department :Neurology
Division : Epilepsy
An Open Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures
 
Principal Investigator: Derek Chong  
Start date: 08/23/2007
End date: 02/28/2018
to request information from Principal Investigator.
   Top of page
An Open-Label extension trial to determine tolerabiltiy and efficacy of long term oral SPM 927 as adjunctive therapy in pateints with partial seizures
 
Principal Investigator: Derek Chong  
Start date: 04/16/2003
End date: 09/18/2009
to request information from Principal Investigator.
   Top of page
Eszopiclone for Insomnia in Epilepsy
 
Principal Investigator: Carl Bazil  
Start date: 10/26/2007
End date: 04/30/2011
to request information from Principal Investigator.
   Top of page
IN Clonazepam - Phase IIa, Open-Label, Proof-of-Concept Study to Evaluate the Efficacy and Pharmacokinetics of Intranasal Clonazepam in Adult Subjects With Epileptic Seizures.
 
Principal Investigator: Lawrence J. Hirsch  
Start date: 04/10/2008
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
RNS - Responsive Neurostimulator System Pivotal Clinical Investigation
 
Principal Investigator: Lawrence J. Hirsch  
Start date: 12/08/2006
End date: 05/31/2010
to request information from Principal Investigator.
   Top of page
Responsive Neurostimulator (RNS) System Long-term Treatment Clinical Investigation
 
Principal Investigator: Lawrence J. Hirsch  
Start date: 06/20/2006
End date: 12/31/2014
to request information from Principal Investigator.
   Top of page
Rufinamide - Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures
 
Principal Investigator: Derek Chong  
Start date: 01/10/2007
End date: 06/30/2012
to request information from Principal Investigator.
   Top of page


Department :Neurology
Division : G H Sergievsky Center
52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study with mild Alzheimer's disease (AD) to investigate the safety and tolerability of repeated subcutaneous injections of CAD106
 
Principal Investigator: Karen Bell  
Start date: 12/12/2008
End date: 06/30/2011
to request information from Principal Investigator.
   Top of page
AAB-001 - MC, randomized, 2-blind, placebo-controlled, multiple ascending dose safety,tolerability, reactogenicity and pharmacokinetic study of Bapineuzumab (AAB-001) administered subcutaneously in subjects with Mild to Moderate Alzheimer Disease
 
Principal Investigator: Karen Bell  
Start date: 03/11/2008
End date: 09/30/2011
to request information from Principal Investigator.
   Top of page
Memantine in FTD - Prospective, Randomized, Multi-Center, Double-Blind 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia.
 
Principal Investigator: Karen Bell  
Start date: 07/08/2008
End date: 06/30/2010
to request information from Principal Investigator.
   Top of page
TPA010RI - 2-blind, placebo-controlled, randomized MC studyevaluating the efficacy and safety of 18 mos. of treatment with PF 04494700 (TTP488) in participants with mild to moderate Alzheimer's Disease
 
Principal Investigator: Karen Bell  
Start date: 08/22/2007
End date: 12/10/2011
to request information from Principal Investigator.
   Top of page
Wyeth ACC-001 in AD - Phase IIa, Multicenter, Randomized, Third-party Unblinded, Adjuvant-controlled, Multiple Ascending Dose, Safety, Tolerability and Immunogenicity Trial of ACC-001 With QS-21 Adjuvant in Patients With Mild to Moderate Alzheimer's Disea
 
Principal Investigator: Karen Bell  
Start date: 10/19/2007
End date: 05/30/2011
to request information from Principal Investigator.
   Top of page
Wyeth SAM-531 in AD - Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics Trial of Multiple Ascending Fixed Doses of SAM-531 in Subjects with Mild to Moderate Alzheimer's Disease.
 
Principal Investigator: Karen Bell  
Start date: 07/30/2007
End date: 01/31/2010
to request information from Principal Investigator.
   Top of page


Department :Neurology
Division : General Neurology
CASSCO - CLOPIDROGREL AND ASPIRIN IN REDUCTION OF CAROTID THICKNESS AND STIFFNESS AFTER STROKE (CASS) TRIAL: Cognitive Outcomes
 
Principal Investigator: Joanne Festa  
Start date: 12/06/2005
End date: 12/31/2010
to request information from Principal Investigator.
   Top of page
Post-Approval Study (PAS) To Monitor the Clinical Performance of the AbioCor%AE in Severe End-Stage Heart Disease Patients.
 
Principal Investigator: Joanne Festa  
Start date: 04/18/2008
End date: 10/31/2009
to request information from Principal Investigator.
   Top of page


Department :Neurology
Division : Movement Disorders
MIRAPEX - Two year open label, randomized, parallel group, bliinded assessment opthalmologic safety study of pramipexole IR vs ropinirole in early Parkinson's disease patients
 
Principal Investigator: Cheryl Waters  
Start date: 07/08/2005
End date: 10/21/2009
to request information from Principal Investigator.
   Top of page
Patch 921 - Multicenter, randomized, double-blind, placebo-controlled, 5-arm, parellel-group trial to assess rotigotine transdermal system dose response in subjects with advanced-stage Parkinson's disease
 
Principal Investigator: Cheryl Waters  
Start date: 12/04/2007
End date: 06/30/2010
to request information from Principal Investigator.
   Top of page
Solvay Open-Label (DuoDopa) - Open-Label, 6-12 Months Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations.
 
Principal Investigator: Cheryl Waters  
Start date: 06/13/2008
End date: 01/31/2010
to request information from Principal Investigator.
   Top of page


Department :Neurology
Division : Movement Disorders/neuromuscular
Two Part, Randomized, Double-Blind, Safety and Tolerability Study Evaluating KNS-760704 in Patients with Amyotrophic Lateral Sclerosis (ALS).
 
Principal Investigator: Jinsy Andrews  
Start date: 05/05/2008
End date: 11/30/2010
to request information from Principal Investigator.
   Top of page


Department :Neurology
Division : Multiple Sclerosis and Demyelinating Diseases
MAESTRO-03 - Double-Blind, Placebo Controlled Multi-Center Study to evaluate the efficacy and Safety of MBP8298 in subjects with secondary progressive Multiple Sclerosis
 
Principal Investigator: Mark Tullman  
Start date: 10/04/2007
End date: 04/30/2011
to request information from Principal Investigator.
   Top of page
MAESTRO-03 - SUB-STUDY: A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 on Visual Function Testing ...in Subjects with Secondary Progressive Multiple Sclerosis
 
Principal Investigator: Mark Tullman  
Start date: 07/07/2008
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
OCRELIZUMAB - Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex® controlled dose finding study to evaluate the efficacy as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with
 
Principal Investigator: Mark Tullman  
Start date: 01/20/2009
End date: 06/30/2014
to request information from Principal Investigator.
   Top of page
OPEN LABEL STUDY OF SAFETY AND TOLERABILITY OF RITUXIMAB© IN NEUROMYELITIS OPTICA, RECURRENT TRANSVERSE MYELITIS AND RECURRENT BILATERAL SIMULTANEOUS OPTIC NEURITIS
 
Principal Investigator: Mark Tullman  
Start date: 04/02/2008
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page


Department :Neurology
Division : Neuromuscular Disease
B for SMA - Pilot Study of Biomarkers for SMA
 
Principal Investigator: Petra Kaufmann  
Start date: 11/26/2008
End date: 05/30/2010
to request information from Principal Investigator.
   Top of page
DMQ and ALS (07-AVR-123) - Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect
 
Principal Investigator: Hiroshi Mitsumoto  
Start date: 03/27/2008
End date: 10/31/2009
to request information from Principal Investigator.
   Top of page
Exercise Testing and A3243G - Exercise Testing in A3243G Mitochondrial Carrier Relatives.
 
Principal Investigator: Petra Kaufmann  
Start date: 01/09/2008
End date: 07/31/2011
to request information from Principal Investigator.
   Top of page
Phase 2b Efficacy and Safety Study jof PTC124 in Subjects with Nonsense-Mutation-Mediated Duchenne Muscular Dystrophy.
 
Principal Investigator: Petra Kaufmann  
Start date: 06/30/2008
End date: 12/31/2010
to request information from Principal Investigator.
   Top of page
TALAMPANEL ALS - Talampanel ALS-201
 
Principal Investigator: Hiroshi Mitsumoto  
Start date: 09/25/2008
End date: 09/01/2010
to request information from Principal Investigator.
   Top of page


Department :Neurology
Division : Neurooncology
**STUDY MANAGER** A Phase I/II Randomized Study of CDX-110 with Radiation and Temozolomide in Patients with Newly Diagnozed Glioblastoma Multiforme
 
Principal Investigator: Rose Lai  
Start date: 04/26/2007
End date: 10/31/2009
to request information from Principal Investigator.
   Top of page
ANG1005-CLN-01 - Phase I, Open-Label, Dose Escalation Study of ANG1005 in Patients with Malignant Glioma.
 
Principal Investigator: Steven Rosenfeld  
Start date: 11/01/2007
End date: 05/31/2010
to request information from Principal Investigator.
   Top of page
ANG1005-CLN-02 - Phase I, Open-Label, Dose Escalation Study of ANG1005 in Patients with Advanced Solid Tumors and Metastatic Brain Cancer.
 
Principal Investigator: Steven Rosenfeld  
Website: angiochem.com
Start date: 11/01/2007
End date: 05/31/2010
to request information from Principal Investigator.
   Top of page
An open-label, multi-center, Phase II study to evaluate the activity of Patupilone (EPO906) in the treatment of recurrent or progressive brain metastases in patients with non-small cell lung cancer.
 
Principal Investigator: Steven Rosenfeld  
Start date: 04/28/2006
End date: 01/31/2010
to request information from Principal Investigator.
   Top of page
Gliogene - Gliogene: An International Consortium to identify susceptibility genes in high-risk familial glioma pedigrees
 
Principal Investigator: Rose Lai  
Start date: 01/07/2008
End date: 07/31/2013
to request information from Principal Investigator.
   Top of page
PCNSL - PCNSL: A Pilot Study of combined Immunochemotherapy Followed by Reduced Dose RT for Patients with Newly Diagnosed PCNSL
 
Principal Investigator: Rose Lai  
Start date: 07/18/2007
End date: 01/31/2010
to request information from Principal Investigator.
   Top of page
Phase I/II BIBW 2992 with or without daily temozolomide in the treatment of patients with recurrent malignant glioma
 
Principal Investigator: Rose Lai  
Start date: 10/30/2008
End date: 04/30/2011
to request information from Principal Investigator.
   Top of page
RECENTIN(tm) - AstraZeneca: A Phase III, Randomised,Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Subjects to Compare the Efficacy of AZD2171 [RECENTIN(tm)] Monotherapy and the Combination of AZD2171 with Lomustine to the Efficacy of Lomust
 
Principal Investigator: Steven Rosenfeld  
Start date: 12/02/2008
End date: 12/02/2011
to request information from Principal Investigator.
   Top of page
TM 601-007 - Phase I Dose Escalation Study Evaluating the Safety and Biologically Active Dose of TM-601 Based on Perfusion MR Imaging Criteria in Patients with Progressive and/or Recurrent Malignant Glioma
 
Principal Investigator: Steven Rosenfeld  
Start date: 01/31/2008
End date: 08/31/2013
to request information from Principal Investigator.
   Top of page
TMI Study - **STUDY MANAGER** A PHASE II OPEN-LABEL, MULTIPLE-DOSE STUDY OF INTRACAVITARY ADMINISTERED 131I-TM-601 IN ADULT PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA
 
Principal Investigator: Steven Rosenfeld  
Start date: 05/07/2007
End date: 11/30/2009
to request information from Principal Investigator.
   Top of page


Department :Neurology
Division : Stroke and Critical Care
ACCELERATE - The evaluation of patients with acute hypertension and intracerebral hemorrhage with intravenous clevidipine treatment.
 
Principal Investigator: Kiwon Lee  
Start date: 05/20/2008
End date: 11/30/2009
to request information from Principal Investigator.
   Top of page
ARUBA - Clinical Trial of Unruptured Brain AVMS-Yr1
 
Principal Investigator: Jay P Mohr  
Website: www.arubastudy.org
Start date: 01/01/2006
End date: .
to request information from Principal Investigator.
   Top of page
COSS - COSS
 
Principal Investigator: Randolph S. Marshall  
Start date: 12/01/2007
End date: 11/30/2012
to request information from Principal Investigator.
   Top of page
RECON - RECON: STUDY OF CAROTID OCCLUSION AND NEUROCOGNITION
 
Principal Investigator: Randolph S. Marshall  
Start date: 12/01/2004
End date: 11/30/2009
to request information from Principal Investigator.
   Top of page
SPS3 - Secondary Prevention of Small SubCordical Strokes (SPS3)
 
Principal Investigator: Mitchell S. Elkind  
Start date: 03/01/2003
End date: 06/30/2011
to request information from Principal Investigator.
   Top of page
STAT Data registry - Studying the Treatment of Acute Hypertension
 
Principal Investigator: Neeraj Badjatia  
Start date: 12/10/2007
End date: 11/30/2009
to request information from Principal Investigator.
   Top of page


Department :Obstetrics and Gynecology
Division : Family Planning & Preventive Services
CCTN - HHSN275200403374I - NICHD Contraceptive Clinicals Network (Female Clinical Trial Topic Area) Yr 1
 
Principal Investigator: Carolyn L. Westhoff  
Start date: 04/01/2004
End date: 03/31/2011
to request information from Principal Investigator.
   Top of page
Feasibility and Acceptability of the Pantarhei Sampler for Cervical Cytology in Low Income Women in New York City
 
Principal Investigator: Carolyn L. Westhoff  
Start date: 09/30/2008
End date: 12/31/2009
to request information from Principal Investigator.
   Top of page


Department :Obstetrics and Gynecology
Division : Gynecologic Oncology
An open-label multi-center randomized Phase 3 study comparing the combination of DOXIL®/CAELYX® and YONDELIS™ with DOXIL®/CAELYX® alone in subjects with advanced relapsed ovarian cancer
 
Principal Investigator: Thomas Herzog  
Start date: 01/19/2006
End date: 01/31/2010
to request information from Principal Investigator.
   Top of page
ChemoFx Registry - An observational, longitudinal, multi-center study examining outcomes associated with the use of the ChemoFx Assay in solid tumor malignancies
 
Principal Investigator: Thomas Herzog  
Start date: 08/29/2007
End date: 02/28/2012
to request information from Principal Investigator.
   Top of page
Oceans Study - Phase II, multicenter, randmoized, blinded, placebo-controlled trial of carboplatin and gemcitabine plus bevacizumab in patients with platinum-sensitive recurrent ovary, primary peritoneal, or fallopian tube carcinoma
 
Principal Investigator: Thomas Herzog  
Start date: 07/18/2007
End date: 01/31/2013
to request information from Principal Investigator.
   Top of page
PILOT PHASE II STUDY EVALUATING THE COMBINATION OF OXALIPLATIN AND DOCETAXEL WITH BEVACIZUMAB AS FIRST LINE THERAPY IN PATIENTS WITH FIGO STAGE IB-IV EPITHELIAL OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE CARCINOMA
 
Principal Investigator: Thomas Herzog  
Start date: 08/25/2006
End date: 02/28/2017
to request information from Principal Investigator.
   Top of page
SINGLE-ARM, OPEN-LABEL, PHASE II STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE TRIFUNCTIONAL ANTIBODY CATUMAXOMAB (ANTI-EPCAM × ANTI-CD3)ADMINISTERED INTRAPERITONEALLY IN OVARIAN CANCER PATIENTS WITH RECURRENT SYMPTOMATIC MALIGNANT ASCITES
 
Principal Investigator: Thomas Herzog  
Start date: 08/01/2006
End date: 02/28/2016
to request information from Principal Investigator.
   Top of page


Department :Obstetrics and Gynecology
Division : Maternal Fetal Medicine
Maternal Fetal Medicine Unit Network at CUMC
 
Principal Investigator: Ronald J. Wapner  
Start date: 04/01/2006
End date: 03/31/2011
to request information from Principal Investigator.
   Top of page


Department :Obstetrics and Gynecology
Division : Menopause
MP
 
Principal Investigator: Michelle P. Warren  
Start date: 10/08/2008
End date: 10/30/2010
to request information from Principal Investigator.
   Top of page
Multi-center, randomized, double-blind, double-dummy study in postmenopausal women with low bone mineral density to compare the effects of a single dose of i.v. zoledronic acid 5 mg, with daily oral raloxifene 60 mg OD on bone turnover markers
 
Principal Investigator: Michelle P. Warren  
Start date: 07/10/2007
End date: 01/31/2010
to request information from Principal Investigator.
   Top of page


Department :Obstetrics and Gynecology
Division : Obstetrics and Gynecology
Antepartum Interpersonal Psychotherapy at 3 NYC Sites - Yr 1
 
Principal Investigator: Jane Cleary-Goldman  
Start date: 09/21/2005
End date: 05/31/2010
to request information from Principal Investigator.
   Top of page
Prospective, Controlled, Randomized, Multi-Center, Phase I/II Study Evaluating the Safety and Efficacy of Adhexil
 
Principal Investigator: Melvin Thornton  
Start date: 10/23/2007
End date: 05/30/2010
to request information from Principal Investigator.
   Top of page


Department :Obstetrics and Gynecology
Division : Reproduction and Endocrinology
DVS SR - Double-blind, randomized, placebo-controlled study assessing the safety and efficacy of DVS SR for the treament of vasomotor symptoms associated with menopause.
 
Principal Investigator: Rogerio A. Lobo  
Start date: 05/14/2008
End date: 05/13/2010
to request information from Principal Investigator.
   Top of page
KEEPS - Effects of estrogen replacement on atherosclerosis progression in recently menopausal women
 
Principal Investigator: Rogerio A. Lobo  
Start date: 11/01/2004
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page


Department :Ophthalmology
Division : Glaucoma
XALATAN - Phase I, Open lable study of latanoprost acid plasma concentrations in pediatric and adult glaucoma patients treated with latanoporst 0.005%
 
Principal Investigator: Lama Al-Aswad  
Start date: 01/22/2009
End date: 07/31/2010
to request information from Principal Investigator.
   Top of page


Department :Ophthalmology
Division : Macula Surgical & Medical Retinal Disease
BRAVO - Phase III Multicenter, Randomized, Sham Injection -Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Branch Retinal Vein Occlusion
 
Principal Investigator: Gaetano Barile  
Start date: 08/09/2007
End date: 06/30/2010
to request information from Principal Investigator.
   Top of page
CRUISE - PHASE III, MULTICENTER, RANDOMIZED, SHAM INJECTION%96CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF RANIBIZUMAB INJECTION COMPARED WITH SHAM IN SUBJECTS WITH MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION
 
Principal Investigator: Gaetano Barile  
Start date: 08/21/2007
End date: 06/30/2010
to request information from Principal Investigator.
   Top of page
GENEN - OL, MC extension sty. to eval the saf and toler of Ranibizumab in subjects with choroidal neovascularization (CNV) secondary to age related macular degeneration (AMD) who have completed the treatment phase of a genentech sponsored ranibizumab stud
 
Principal Investigator: Gaetano Barile  
Start date: 09/16/2005
End date: 12/31/2009
to request information from Principal Investigator.
   Top of page


Department :Ophthalmology
Division : Ophthalmology
CORNEAL ECTASIA - Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes with Corneal Ectasia after Refractive Surgery.
 
Principal Investigator: Stephen Trokel  
Start date: 06/21/2008
End date: 06/16/2010
to request information from Principal Investigator.
   Top of page
UVX Illumination System - Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes with Progressive Keratoconus.
 
Principal Investigator: Stephen Trokel  
Start date: 06/17/2008
End date: 06/16/2010
to request information from Principal Investigator.
   Top of page


Department :Ophthalmology
Division : Other
CLEAR-IT 3 - Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration (CLEAR-IT 3), Protocol VGFT-OD-06
 
Principal Investigator: Stanley Chang  
Start date: 09/18/2007
End date: 03/31/2011
to request information from Principal Investigator.
   Top of page
Randomized, placebo controlled, 2-masked, mc trial of microplasmin intravitreal injection for non-surgical treatment of focal vitreomacular adhesion.
 
Principal Investigator: Stanley Chang  
Start date: 02/02/2009
End date: 07/31/2010
to request information from Principal Investigator.
   Top of page


Department :Orthopedic Surgery
Division : Lower Extremity and Reconstruction
GEM OS1 For Ankle Fusion - Prospective, randomized, controlled, pivotal human clinical trial to evaluate the safety and effectiveness of GEM OS1 compared to autologous bone graft as a bone regeneration device in foot and ankle fusions.
 
Principal Investigator: Justin Greisberg  
Start date: 03/27/2008
End date: 09/30/2009
to request information from Principal Investigator.
   Top of page
Wright Medical Ceramic-on-Metal Total Hip Arthroplasty IDE Study
 
Principal Investigator: William B. Macaulay  
Start date: 11/20/2008
End date: 05/31/2011
to request information from Principal Investigator.
   Top of page
rhBMP-2/CPM - Phase 2, MC, randomized, active controlled parallel group dose finding and safety study of recombinant human bone morphogenetic protein in subjects with decreased bone mineral density
 
Principal Investigator: William B. Macaulay  
Start date: 11/21/2008
End date: 05/31/2014
to request information from Principal Investigator.
   Top of page


Department :Otolaryngology/head and Neck Surgery
Division : Head & Neck Surgery
Evaluation of music benefits in adults with HiResolution Fidelity 120 sound processing music benefits in HighRes 120
 
Principal Investigator: Jaclyn B. Spitzer  
Start date: 11/18/2008
End date: 05/30/2011
to request information from Principal Investigator.
   Top of page


Department :Pathology
Division : Hemopathology
Safety and Effectiveness in a Multi-Center Randomized, Sham-Controlled Investigation for Dry, Non-Exudative Age Related Macular Degeneration Using Rheopheresis
 
Principal Investigator: Joseph Schwartz  
Start date: 08/20/2007
End date: 06/30/2010
to request information from Principal Investigator.
   Top of page


Department :Pediatrics
Division : Autoimmune & Molecular Diseases
MDX-1342 - A Phase 1, Single-blind, Randomized, Placebo-controlled, Multicenter, Single-dose, Dose-escalation Safety & Tolerability Study of MDX-1342 in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis
 
Principal Investigator: Robert Winchester  
Start date: 04/21/2008
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page


Department :Pediatrics
Division : Cardiology
AGA Closure of ventricular septal defects with the amplatzer muscular VSD occluder
 
Principal Investigator: William E. Hellenbrand  
Start date: 10/21/2008
End date: 04/30/2014
to request information from Principal Investigator.
   Top of page
ARIES-3 - Phase 3. Lomg-term, Open-label, Multicenter Safety and Efficacy Study of Ambrisentan in Subjects with Pulmonary Hypertension.
 
Principal Investigator: Erika S. Berman-Rosenzweig  
Start date: 01/25/2007
End date: 07/31/2010
to request information from Principal Investigator.
   Top of page
ASD PMS II - Closure of Atrial Septal Defects With the AMPLATZER Septal Occluder Post Market Study
 
Principal Investigator: William E. Hellenbrand  
Start date: 06/20/2008
End date: 08/31/2011
to request information from Principal Investigator.
   Top of page
ASSET 3 - Long-term, open-label, multicenter extension study of bosentan in patients with pulmonary hypertension associated with sickle cell disease completing a double-blind ASSET study
 
Principal Investigator: Erika S. Berman-Rosenzweig  
Start date: 03/14/2007
End date: 09/30/2010
to request information from Principal Investigator.
   Top of page
COAST - Coarctation of the Aorta Stent Trial (COAST)
 
Principal Investigator: William E. Hellenbrand  
Start date: 04/16/2008
End date: 06/30/2014
to request information from Principal Investigator.
   Top of page
COMPASS 3 - An Open-label, Multi-Center Study Employing a Targeted 6-MWT Distance Threshold Approach to Guide Bosentan-Based Therapy and to Assess the Utility of MRI on Cardiac Remodeling
 
Principal Investigator: Robyn J. Barst  
Start date: 06/12/2007
End date: 12/31/2010
to request information from Principal Investigator.
   Top of page
Cardiolite 301 - Phase III, open-label, non-randomized, international multicenter trial to evaluate the efficacy and safety of cardiolite myocardial perfusion imaging in pediatric subjects with kawasaki disease
 
Principal Investigator: Ashwin Prakash  
Start date: 01/17/2006
End date: 07/31/2017
to request information from Principal Investigator.
   Top of page
Gleevec - Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of 6 months of treatment with tyrosine kinase inhibitor STI571 for the treatment of pulmonary arterial hypertension.
 
Principal Investigator: Erika S. Berman-Rosenzweig  
Start date: 08/17/2007
End date: 02/28/2011
to request information from Principal Investigator.
   Top of page
MEDTRON - Chronicle Implantable Hemodynamic Monitoring System Pulmonary Arterial Hypertension Pilot Study
 
Principal Investigator: Erika S. Berman-Rosenzweig  
Start date: 03/29/2004
End date: 06/30/2010
to request information from Principal Investigator.
   Top of page
MELODY - Implantation of the Medtronic Transcatheter Pulmonary Valve in Patients wiht Dysfunctional Right Ventricular Outflow Tract (RVOT) Conduits: A Feasibility Study
 
Principal Investigator: William E. Hellenbrand  
Start date: 03/26/2007
End date: 09/30/2011
to request information from Principal Investigator.
   Top of page
Method for Evaluating and Improving Outcomes in Pediatric Cardiac Catheterizations
 
Principal Investigator: William E. Hellenbrand  
Start date: 01/23/2007
End date: 07/31/2011
to request information from Principal Investigator.
   Top of page
PFIZER - Continuation Study of Sildenafil and Flolan when used in combination
 
Principal Investigator: Erika S. Berman-Rosenzweig  
Start date: 06/30/2003
End date: 06/30/2010
to request information from Principal Investigator.
   Top of page
PHIRST - An Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension
 
Principal Investigator: Erika S. Berman-Rosenzweig  
Start date: 12/23/2005
End date: 06/30/2010
to request information from Principal Investigator.
   Top of page
REVEAL Registry - Registry to Evaluate Early and Long-term PAH Disease Management
 
Principal Investigator: Erika S. Berman-Rosenzweig  
Start date: 10/12/2006
End date: 04/30/2014
to request information from Principal Investigator.
   Top of page
SERAPHIN - Study with endothelin receptor antagonist in pulmonary arterial hypertension to improve clinical outcome
 
Principal Investigator: Erika S. Berman-Rosenzweig  
Start date: 02/03/2009
End date: 08/31/2011
to request information from Principal Investigator.
   Top of page
pfizer - MC Long Term Extension Study to Assess the Safety of Oral Sildenafil in the Treatment of Subjects who have completed study 1131
 
Principal Investigator: Robyn J. Barst  
Start date: 01/23/2004
End date: 06/30/2010
to request information from Principal Investigator.
   Top of page
seraphin ol - Long term single arm OL extension study of the Seraphin Stuy to assess the safety and tolerability of ACT 064992 in patients with symptomatic pu,onary arterial hypertension
 
Principal Investigator: Erika S. Berman-Rosenzweig  
Start date: 02/03/2009
End date: 08/31/2015
to request information from Principal Investigator.
   Top of page


Department :Pediatrics
Division : Endocrinology
Post Marketing Surveillance program for Protropin (Somatrem for injection) and Nutropin (Somatropin for injection)
 
Principal Investigator: Sharon Oberfield  
Start date: 07/01/1994
End date: 12/31/2011
to request information from Principal Investigator.
   Top of page


Department :Pediatrics
Division : Gastroenterology & Nutrition
ALF PEDS - U01 DK072146/A Multi-Center Group to Study Acute Liver Failure in Children
 
Principal Investigator: Steven J. Lobritto  
Start date: 09/01/2005
End date: 08/31/2010
to request information from Principal Investigator.
   Top of page
Phase 3 double-Blind, Randomized, Placebo-Controlled Study of the Safety adn Efficacy of Adefovir Dipivoxil in Children and Adolescents with Chronic Hepatitis B
 
Principal Investigator: Steven J. Lobritto  
Start date: 10/14/2004
End date: 12/31/2009
to request information from Principal Investigator.
   Top of page


Department :Pediatrics
Division : Hematology and Blood and Marrow Transplant
Clofarabine in Combination with Cytarabine and Total Body Irradiation Followed by Allogeneic Stem Cell Transplantation in Children with Acute Lymphoblastic Leukemia and Acute Non-Lymphoblastic Leukemia in Third Complete Remission
 
Principal Investigator: Mitchell S. Cairo  
Start date: 05/30/2007
End date: 11/30/2009
to request information from Principal Investigator.
   Top of page
SUBCONTRACT for Clofarabine in combination with cytarabine and total body irradiation followed by allogeneic stem cell transplantation in children with acute lymphoblastic leukemia and acute non-lymphoblastic leukemia in third complete remission.
 
Principal Investigator: Mitchell S. Cairo  
Start date: 12/02/2007
End date: 06/30/2010
to request information from Principal Investigator.
   Top of page


Department :Pediatrics
Division : Infectious Diseases
2304 - MC, OL, SA, 2-step study to evaluate the safety and single dose pharmacokinetics of famciclovir and multiple-dose safety after administration of famciclovir oral pediatric formulation to children 1-12 years of age with Herpes simplex infection
 
Principal Investigator: Natalie Neu  
Start date: 05/27/2005
End date: 11/30/2009
to request information from Principal Investigator.
   Top of page
HPV Vaccine - Study to Evaluate the efficacy of Quadrivalent HPV (Types 6, 11, 16, & 18) L1 virus-like particle in reducing the incidence of HPV 6-,11-,16-, &18 related genital warts, & the Incidence of HPV & related Genital Infection in 16-23 years
 
Principal Investigator: Natalie Neu  
Start date: 04/19/2005
End date: 10/31/2009
to request information from Principal Investigator.
   Top of page
Tygacil in PEDS - Multicenter, Open-Label, Ascending Multiple-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age With Selected Serious Infections
 
Principal Investigator: Natalie Neu  
Start date: 10/05/2007
End date: 05/31/2010
to request information from Principal Investigator.
   Top of page


Department :Pediatrics
Division : Neonatology & Perinatal Medicine
Long Term Follow Up After Head Cooling For Neonatal Encephalopathy Abbreviated Title: Brain Cooling Long Term Follow Up
 
Principal Investigator: Richard A Polin  
Start date: 01/04/2008
End date: 07/31/2010
to request information from Principal Investigator.
   Top of page


Department :Pediatrics
Division : Oncology
Phase 1/Phase 2 Study of CP-751,871 in Patients With Relapsed and/or Refractory Ewings Sarcoma Family of Tumors. Abbreviated Title: Pfizer: A4021020-1018
 
Principal Investigator: Linda Granowetter  
Start date: 07/31/2007
End date: 07/31/2012
to request information from Principal Investigator.
   Top of page
Phase I/II Safety and Exploratory Pharmacodynamic Study of Intravenous Temsirolimus (CCI-779) in Pediatric Subjects with Relapsed/Refractory Solid Tumors
 
Principal Investigator: Julia Glade-Bender  
Start date: 07/28/2007
End date: 01/31/2010
to request information from Principal Investigator.
   Top of page
RASALL - Study of rasburicase treatment for chemotherapy or malignancy-induced hyperuricemia in patients with a history of asthma or allergies
 
Principal Investigator: Kara Kelly  
Start date: 10/13/2008
End date: 03/31/2012
to request information from Principal Investigator.
   Top of page
Study of Bortezomib with Chemotherapy for Relapsed/Refractory Acute Lymphoblastic Leukemia
 
Principal Investigator: Julia Glade-Bender  
Start date: 01/16/2008
End date: 07/31/2010
to request information from Principal Investigator.
   Top of page


Department :Pediatrics
Division : Pulmonary
Inner-City Anti-IgE Therapy for Asthma (ICATA)
 
Principal Investigator: Meyer Kattan  
Start date: 09/18/2007
End date: 03/31/2010
to request information from Principal Investigator.
   Top of page


Department :Pediatrics
Division : Rheumatology
APPLE - The Atherosclerosis Prevention in Pediatric Lupus Erythematosus
 
Principal Investigator: Lisa Imundo  
Start date: 12/01/2003
End date: 11/30/2009
to request information from Principal Investigator.
   Top of page


Department :Psychiatry
Division : Behavioral Medicine
OLZ and Task Engagement - Efficacy of Olanzapine in Improving Task Engagement in Schizophrenia.
 
Principal Investigator: Jimmy Choi  
Start date: 03/20/2008
End date: 09/30/2010
to request information from Principal Investigator.
   Top of page


Department :Psychiatry
Division : Child Psychiatry
DVSSR3151A62000 - Multicenter, open-label, safety, tolerability and pharmacokinetic study to evaluate single ascending doses and subsequent short-term administration of fixed doses of desvenlafaxine...
 
Principal Investigator: Moira A Rynn  
Start date: 03/15/2008
End date: 05/19/2010
to request information from Principal Investigator.
   Top of page


Department :Psychiatry
Division : Geriatrics
Multi-center, open-label study in healthy 55-80 year old volunteers and patients with affective and anxiety disorders to characterize the regional distribution of [11C] ABP-688 in brain by positron emission tomography (PET)
 
Principal Investigator: Devangere P. Devanand  
Start date: 06/05/2007
End date: 12/31/2009
to request information from Principal Investigator.
   Top of page


Department :Psychiatry
Division : Neuroscience
PET Evaluation of Serotonin and Dopamine Transporter Occupancy Associated with Oral Administration of Single Doses of SEP-225289 to Healthy Volunteers
 
Principal Investigator: Ramin Parsey  
Start date: 12/07/2007
End date: 06/30/2010
to request information from Principal Investigator.
   Top of page


Department :Psychiatry
Division : Other
Randomized, Double-Blind, Placebo-Controlled, Risperidone-Referenced, Parallel-Group, Adaptive-Design study of the Efficacy, Safety, and Tolerability of Vabicaserin (SCA-136) in Subjects with Acute Exacerbations of Schizophrenia
 
Principal Investigator: Jeffrey A. Lieberman  
Start date: 10/18/2007
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page


Department :Psychiatry
Division : Substance Abuse
Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Probuphine in Patients with Opioid Dependence
 
Principal Investigator: Maria A. Sullivan  
Start date: 10/03/2007
End date: 09/30/2009
to request information from Principal Investigator.
   Top of page


Department :Radiation Oncology
Division : Radiation Oncology
Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth, rHuKGF) for the Reduction of Oral Mucositis in Subjects with Advanced Head and Neck Can
 
Principal Investigator: Peter Schiff  
Start date: 05/24/2006
End date: 11/30/2015
to request information from Principal Investigator.
   Top of page


Department :Radiology
Division : Interventional Radiology
RENAISSANCE - Prospective Multicenter Single Arm Study Evaluating the Express Renal Premounted Stent System in the Treatment of Atherosclerotic Lesions in the Aortorenal Ostium
 
Principal Investigator: Ziv J. Haskal  
Start date: 07/14/2004
End date: 03/31/2010
to request information from Principal Investigator.
   Top of page
REX VENA CAVA FILTER - DEVICE STUDY: Rex Medical Option Vena Cava Filter Clinical Trial
 
Principal Investigator: Ziv J. Haskal  
Start date: 07/18/2007
End date: 01/31/2013
to request information from Principal Investigator.
   Top of page


Department :Radiology
Division : Neurosurgery
CARNEROS 1 - Phase 2, MC, Open Label, Two Stage Study to Evaluate the Saftey and Efficacy of Intra-Arterial Catheter-Directed Alfimeprase for Restoration of Neurologic Funtion and Rapid Opening of Arteries in Stroke
 
Principal Investigator: Philip M. Meyers  
Start date: 12/05/2007
End date: 06/30/2013
to request information from Principal Investigator.
   Top of page
Evaluation of the Penumbra Stroke System in the Revascularization of Patients with Acute Ischemic Stroke Secondary to Intracranial Large Vessel Occlusive Disease
 
Principal Investigator: Philip M. Meyers  
Start date: 01/09/2007
End date: 07/31/2012
to request information from Principal Investigator.
   Top of page


Department :School Of Dental and Oral Surgury
Division : Periodontics
Phase 2B Trial of Transmucosal Herbal Periodontal Patch in Subjects With Gingivitis.
 
Principal Investigator: John Grbic  
Start date: 06/08/2008
End date: 12/31/2009
to request information from Principal Investigator.
   Top of page


Department :Surgery
Division : Allen General Surgery
GPS - **STUDY MANAGER** Prospective randomized trial comparing medical therapy to weight loss surgery in type 2 diabetics with BMI 30-35. Abbreviated Title: Diabetes Surgery Study
 
Principal Investigator: William B. Inabnet  
Start date: 06/01/2008
End date: 05/31/2010
to request information from Principal Investigator.
   Top of page


Department :Surgery
Division : Cardiothoracic Surgery
**STUDY MANAGER** Evaluation of the VentrAssist Left Ventricular Assist Device as a Bridge to Cardiac Transplantation-Pivotal Trial
 
Principal Investigator: Yoshifumi Naka  
Start date: 09/12/2007
End date: 03/31/2010
to request information from Principal Investigator.
   Top of page
**STUDY MANAGER** Prospective, multi-center, randomized clinical investigation of transmedics organ care system (OCS) for cardiac use
 
Principal Investigator: Yoshifumi Naka  
Start date: 10/16/2008
End date: 04/30/2011
to request information from Principal Investigator.
   Top of page
**STUDY MANAGER** The Evaluation of the Safety and Effectiveness of the Duraheart Left Ventricular Assist System in Patients Awaiting Transplantation
 
Principal Investigator: Yoshifumi Naka  
Start date: 10/13/2008
End date: 04/30/2011
to request information from Principal Investigator.
   Top of page
G050203 - **STUDY MANAGER** An Observational, Prospective Evaluation of the Trifecta Valve
 
Principal Investigator: Allan S. Stewart  
Start date: 12/13/2007
End date: 06/30/2011
to request information from Principal Investigator.
   Top of page
MAGRIT - Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with Non-Small Cell Lung Cancer
 
Principal Investigator: Joshua Sonett  
Start date: 09/18/2007
End date: 03/31/2018
to request information from Principal Investigator.
   Top of page
Relay Trial - **STUDY MANAGER** A Phase II Clinical Study of the Safety and Efficacy of the Relay Thoracic Stent-Graft in Patients with Thoracic Aortic Pathologies
 
Principal Investigator: Allan S. Stewart  
Start date: 08/23/2007
End date: 06/30/2014
to request information from Principal Investigator.
   Top of page
Vaccine V710 - **STUDY MANAGER** A randomized, MC, 2-blind, Group sequential study to evaluate the efficacy, immunogenicity and safety of a single dose of Merck 0657nI Staphyloccoccus aureus Vaccine V710 in adult patients scheduled
 
Principal Investigator: Michael Argenziano  
Start date: 09/30/2008
End date: 09/15/2011
to request information from Principal Investigator.
   Top of page
Ventrassist LVAD - **STUDY MANAGER** Evaluation of the VentrAssist Left Ventricular Assist Device for the Treatment of Advanced Heart Failure-Destination Therapy
 
Principal Investigator: Yoshifumi Naka  
Start date: 01/31/2008
End date: 08/31/2010
to request information from Principal Investigator.
   Top of page


Department :Surgery
Division : Center For Liver Disease & Transplantation
**STUDY MANAGER** A Phase 2, Ramdomized, Open-Label study of the Safety, Antiviral Activity, Peginterferon Alfa 2B (Peg-intron) plus Ribavirn (Rebetol) versus peg-intron plus rebetol in subjects with hepatitits c virus Genotype 1 infection
 
Principal Investigator: Robert S. Brown  
Start date: 03/29/2007
End date: 09/30/2009
to request information from Principal Investigator.
   Top of page
**STUDY MANAGER** A Phase 3 Study of 2 dose Regimens of Telaprevir in Combination with Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects with Genotype 1 Chronic Hepatitis C.
 
Principal Investigator: Robert S. Brown  
Start date: 05/27/2008
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page
**STUDY MANAGER** Comparison of Weight-based Dosed of Taribavirin with Peginterferon Alfa-2b Versus Ribavirin Combined with Peginterferon Alfa-2b in Therapy-naive Patients with Chronic Hepatitis C Virus Genotype 1 Infection
 
Principal Investigator: Robert S. Brown  
Start date: 06/29/2007
End date: 12/31/2009
to request information from Principal Investigator.
   Top of page
AI463-901 - **STUDY MANAGER** A Preliminary Assessment of Safety and Antiviral Activity of Open-Label Entecavir Plus Lamivudine Therapy in Subjects with Chronic Hepatitis B who have Viremia on Monotherapy in other Entecavir Trials
 
Principal Investigator: Robert S. Brown  
Start date: 04/17/2003
End date: 12/31/2009
to request information from Principal Investigator.
   Top of page
CTI - **STUDY MANAGER** Safety and Efficacy of the extracorporeal liver assist device (Elad) in patients with acute on chronic hepatitis (AOCH)
 
Principal Investigator: Robert S. Brown  
Start date: 01/19/2009
End date: 07/19/2010
to request information from Principal Investigator.
   Top of page
GILEAD-0108 - **STUDY MANAGER** A Phase 2, Double-Blind, Multi-center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatment of Chronic Hepatitis B Subjects
 
Principal Investigator: Robert S. Brown  
Start date: 03/23/2006
End date: 09/30/2009
to request information from Principal Investigator.
   Top of page
GlobeImmune - **STUDY MANAGER** Phase 2 Randomized, Open Label, Multi-center, Therapeutic Trial of the Efficacy, Immunogenicity, and Safety of GI-5005; and Inactivated Recombinant Saccharomyces Cerevisiae Expressing a Hepatitis C Virus
 
Principal Investigator: Robert S. Brown  
Start date: 01/02/2008
End date: 07/31/2010
to request information from Principal Investigator.
   Top of page
MORE Registry - MORE Registry (Mycophenolic acid Observational Renal Transplant Program) A Phase IV, multi-center, prospective, observational study of the safety, effectiveness and tolerability of immunosuppressant regimens to treat renal transplant patie
 
Principal Investigator: Lloyd Ratner  
Start date: 12/10/2007
End date: 06/30/2013
to request information from Principal Investigator.
   Top of page
Maribavir 1263-301 - **STUDY MANAGER** A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylatic use of Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegaloviurs Disease in Recipients of Orthotopic Liver Transplants
 
Principal Investigator: Robert S. Brown  
Start date: 09/04/2007
End date: 01/30/2010
to request information from Principal Investigator.
   Top of page
NABI-4204 Follow-up - Clinical Trial to Collect Long Term Follow-up Data for Orthotopic Liver Transplantation Subjects Previously Enrolled in the Nabi-4204 Study.
 
Principal Investigator: Robert S. Brown  
Start date: 01/18/2008
End date: 07/31/2010
to request information from Principal Investigator.
   Top of page
PATHWAY - Prospective, randomised, double-blind, placebo-controlled, parallel-group, international multicentre phase III trial of PI88-in the adjuvant treatment of post-resection hepatocullar carcinoma.
 
Principal Investigator: Jean Emond  
Start date: 06/30/2008
End date: 11/30/2010
to request information from Principal Investigator.
   Top of page
RAD001 - **STUDY MANAGER** 24 Month, Multi-center, Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de novo
 
Principal Investigator: Robert S. Brown  
Start date: 05/21/2008
End date: 01/04/2012
to request information from Principal Investigator.
   Top of page
RFHE3002 - **STUDY MANAGER** A Multicenter, Open-Label Trial to Evaluate ihe Long-Term Safety and Tolerabilty of Rifaximin 550 MG BID in Subjects with a History of Hepatic Encephalopathy
 
Principal Investigator: Robert S. Brown  
Start date: 06/07/2007
End date: 12/31/2009
to request information from Principal Investigator.
   Top of page
SPRINT STUDY - Safety and Efficacy Study of SCH 503034 in Previouosly Untreated Subjects with Chronic Hepatitis C Infected With Genotype 1
 
Principal Investigator: Robert S. Brown  
Start date: 03/31/2007
End date: 09/30/2010
to request information from Principal Investigator.
   Top of page
Sprint Follow Up PO5063 - ** STUDY MANAGER** Long-Term Follow-Up of Subjects in a Phase 2 or 3 Clinical Trial in which SCH 503034 was administered for the Treatment of Chronic Hepatitis C
 
Principal Investigator: Robert S. Brown  
Start date: 03/11/2008
End date: 09/30/2010
to request information from Principal Investigator.
   Top of page
VX08-950-111 - **STUDY MANAGER** A Randomized study of stopping treatment at 24 wks vs cont.treatment to 48 wks in treatment-naive subject with Genotype 1 Chronic hepatitis C who acieve and eRVR while rcv'ing Telaprevir, Pegasys and Copegus
 
Principal Investigator: Robert S. Brown  
Start date: 11/06/2008
End date: 05/30/2011
to request information from Principal Investigator.
   Top of page
Vertex Rollover - ** STUDY MANAGER** A Phase 2 Rollover Protocol of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys%AE) and Ribavirin (Copegus%AE) in Subjects Enrolled in
 
Principal Investigator: Robert S. Brown  
Start date: 04/23/2008
End date: 10/31/2010
to request information from Principal Investigator.
   Top of page


Department :Surgery
Division : Surgical Oncology
ACOSOG - American College of Surgeon Oncology Group (ACOSOG) U10 CA76001
 
Principal Investigator: Bret Taback  
Start date: 08/30/2006
End date: 08/29/2016
to request information from Principal Investigator.
   Top of page
Allovectin - Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7 compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma
 
Principal Investigator: Howard L. Kaufman  
Start date: 08/30/2007
End date: 03/31/2014
to request information from Principal Investigator.
   Top of page
Bay 43-9006 - Phase 1 Open-Label, Dose-Finding Study of BAY 43-9006 (sorafenib) in high-risk hepatocellular cancer patients after liver transplantation.
 
Principal Investigator: Abby Siegel  
Start date: 01/21/2009
End date: 07/31/2013
to request information from Principal Investigator.
   Top of page
COMPASSION USE STUDY: A Multicenter Treatment Protocol for compassionate Use of Ipilimumab monotherapy in subjects with resectable stage III or Stage IV melanoma.
 
Principal Investigator: Howard L. Kaufman  
Start date: 06/06/2008
End date: 11/30/2010
to request information from Principal Investigator.
   Top of page
New Vaccine for Kidney Cancer
 
Principal Investigator: Howard L. Kaufman  
Start date: 10/01/2007
End date: 09/30/2009
to request information from Principal Investigator.
   Top of page
Phase II Trial of sequntial high dose interleukin 3 followed by temozolomide and gm-csf in metastatic melanoma
 
Principal Investigator: Howard L. Kaufman  
Start date: 10/03/2005
End date: 04/30/2011
to request information from Principal Investigator.
   Top of page
Preliminary Study of the Safety, Immunogenicity and Clinical Efficacy of Trovax Given in Conjunction with Interleukin 2 (IL-2) in the Treatment of Stage IV Renal Cell Cancer Prelim Study of Trovax eith IL-2 for Stage IV Renal Cancer
 
Principal Investigator: Howard L. Kaufman  
Start date: 08/26/2004
End date: 11/30/2009
to request information from Principal Investigator.
   Top of page
Randomized, DB, MC study comparing MDX-010 Monotherapy, MDX-010 in Combination with a Melanoma Peptide Baccine, and Melanoma Vaccine, & Melanoma Vaccine Monotherapy in HLA-A*0201-Positive Pts w/ Previously treated unresectable stage III or IV Melanoma
 
Principal Investigator: Howard L. Kaufman  
Start date: 07/12/2005
End date: 01/31/2011
to request information from Principal Investigator.
   Top of page


Department :Surgery
Division : Surgical Specialties
Study of the Perioperative use of Cetuximab in Colon Cancer Patients
 
Principal Investigator: Richard L. Whelan  
Start date: 11/20/2007
End date: 05/31/2010
to request information from Principal Investigator.
   Top of page
ToGA - **STUDY MANAGER** TOGa™: A Randomized, Sham-Controlled Trial to Assess the Safety and Effectiveness of Transoral Gastroplasty in the Treatment of Morbid Obesity.
 
Principal Investigator: Marc Bessler  
Start date: 05/23/2008
End date: 06/30/2010
to request information from Principal Investigator.
   Top of page


Department :Surgery
Division : Vascular Surgery
**STUDY MANAGER** Evaluation of the Zilver PTX Vascular Stent in the Above-the-Knee Femoropoliteal Artery (Phase 2 Study)
 
Principal Investigator: Nicholas J. Morrissey  
Start date: 08/09/2007
End date: 02/28/2013
to request information from Principal Investigator.
   Top of page
BENEFIT - **STUDY MGR** Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT
 
Principal Investigator: Mark A. Hardy  
Start date: 10/16/2006
End date: 04/30/2010
to request information from Principal Investigator.
   Top of page
Benefit-EXT IM103-027 - Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immuno- suppression Trial - EXTended criteria donors (BENEFIT - EXT)
 
Principal Investigator: Mark A. Hardy  
Start date: 11/03/2006
End date: 05/31/2010
to request information from Principal Investigator.
   Top of page
CHOICE-82910 - **STUDY MANAGER** CAROTID STENTING FOR HIGH SURGICAL RISK PATIENTS; EVALUATING OUTCOMES THROUGH THE COLLECTION OF CLINICAL EVIDENCE (“CHOICE”)
 
Principal Investigator: James F McKinsey  
Start date: 06/26/2007
End date: 12/31/2012
to request information from Principal Investigator.
   Top of page
CREATE PAS - ** STUDY MANAGER** Carotid Revascularization with EV3 Arterial Technology Evolution Post Approval Study
 
Principal Investigator: John Karwowski  
Start date: 07/18/2007
End date: 01/31/2013
to request information from Principal Investigator.
   Top of page
Dermal-LSR - Pivotal study to evaluate the efficacy and safety of Dermal - Living Skin Replacement (Dermal-LSR) in the treatment of chronic diabetic foot ulcers
 
Principal Investigator: Nicholas J. Morrissey  
Start date: 03/09/2007
End date: 09/30/2011
to request information from Principal Investigator.
   Top of page
ENOVUS - Phase II evaluation of the safety and efficacy of the Trivascular ENOVUS Stent Graft System in the treatment of abdominal aortic aneurysms
 
Principal Investigator: James F McKinsey  
Start date: 08/18/2005
End date: 02/28/2011
to request information from Principal Investigator.
   Top of page
Endovascular Exclusion of AAA in High Risk Patients with Large Aortic and Iliac Artery Anatomy
 
Principal Investigator: James F McKinsey  
Start date: 02/27/2006
End date: 08/31/2011
to request information from Principal Investigator.
   Top of page
FUSION / ACCESS - Prospective Multicenter trial of the FUSION Vascular Access graft for patients who require early vascular access for hemodialysis
 
Principal Investigator: Nicholas J. Morrissey  
Start date: 12/15/2005
End date: 06/30/2010
to request information from Principal Investigator.
   Top of page
Fenestrated-AAA - **STUDY MANAGER** Study Assessing Safety and Effectiveness of Perivisceral Aortic Aneurysm Treatment With the Zenith Fenestrated AAA Endovascular Graft and the Effects on Organ and Extremity Perfusion.
 
Principal Investigator: James F McKinsey  
Start date: 02/04/2008
End date: 08/31/2015
to request information from Principal Investigator.
   Top of page
LEAP - Two-Part, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Simvastatin, Losartan and Pioglitazone on Cardiovascular Disease Biomarkers in Lower Extremity Atherosclerotic Plaque Excised from Patients
 
Principal Investigator: James F McKinsey  
Start date: 10/12/2006
End date: 04/30/2012
to request information from Principal Investigator.
   Top of page
OASIS - Clinical Study of the Orbital Atherectomy System for the Treatment of Peripheral Vascular Stenosis
 
Principal Investigator: James F McKinsey  
Start date: 03/27/2007
End date: 09/30/2011
to request information from Principal Investigator.
   Top of page
PROOF - Plaque Removal versus Open Bypass Surgery For Critical Limb
 
Principal Investigator: Nicholas J. Morrissey  
Start date: 06/22/2007
End date: 12/31/2013
to request information from Principal Investigator.
   Top of page
PYTHAGORAS - **STUDY MANAGER** Prospective aneurYsm Trial: High AnGle AORfix™ bifurcAted Stent graft
 
Principal Investigator: James F McKinsey  
Start date: 11/07/2006
End date: 05/31/2012
to request information from Principal Investigator.
   Top of page
Phase II/III, Randomized, Open-label, Active-controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Efalizumab Compared With Cyclosporine, Both in Combination With Mycophenolate Mofetil and Corticosteroids...de novo Renal Transplantation.
 
Principal Investigator: Mark A. Hardy  
Start date: 09/01/2008
End date: 12/01/2010
to request information from Principal Investigator.
   Top of page
Randomized, Double-Blind, Placebo-Controlled, Dose response study of the safety and efficacy of Thymosin Beta 4 in the treatment of Patients with Pressure Ulcers
 
Principal Investigator: Mark A. Hardy  
Start date: 03/09/2006
End date: 11/07/2009
to request information from Principal Investigator.
   Top of page
SONOMA - **STUDY MANAGER** A Carotid Stenting Surveillance Program
 
Principal Investigator: James F McKinsey  
Start date: 09/04/2007
End date: 03/31/2013
to request information from Principal Investigator.
   Top of page
SWIFT - Femoropopliteal DiSease Treated With the SilverHawk Plaque Excision System: A Prospective Registry wIth Duplex Ultrasound Follow Up at Twelve months
 
Principal Investigator: James F McKinsey  
Start date: 10/12/2006
End date: 04/30/2010
to request information from Principal Investigator.
   Top of page
VALOR - Evaluation of the Medtronic AVE Talent Thoracic Stent Graft System for Treatment of Thoracic Aortic Aneurysms
 
Principal Investigator: James F McKinsey  
Start date: 03/31/2004
End date: 12/31/2010
to request information from Principal Investigator.
   Top of page
VIVA - **STUDY MANAGER** The ViVEXX Carotid Revascularization Trial (VIVA) for High Surgical Risk Patients with Rxtracranial Carotid Artery Stenosis using the Bard ViVEXX Carotid Stent and Emboshield BareWire Rapid Exchange Embolic Protection System
 
Principal Investigator: James F McKinsey  
Start date: 03/08/2006
End date: 09/30/2010
to request information from Principal Investigator.
   Top of page
Zenith - **STUDY MANAGER** Zenith TX2 THORACIC TAA Endovascular Graft Clinical Trial Protocol
 
Principal Investigator: James F McKinsey  
Start date: 02/06/2004
End date: 12/31/2009
to request information from Principal Investigator.
   Top of page


Department :Urology
Division : Oncology
Combined Phase I & Phase II Trial of Intravesical Abraxane, a Biologically Interactive Albumin-Bound Paclitaxel, in the Treatment of Refractory Superficial Transitional Cell Bladder Cancer
 
Principal Investigator: James McKiernan  
Start date: 01/09/2008
End date: 07/31/2011
to request information from Principal Investigator.
   Top of page
Comparative Study of PET/CT versus Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients with Renal Masses Using Iodine-124 labeled Chimeric G250
 
Principal Investigator: James McKiernan  
Start date: 08/01/2008
End date: 06/30/2010
to request information from Principal Investigator.
   Top of page
Multicenter, Open-Label, Randomized, Phase III Trial Comparing Immediate ADjuvant Hormonal Therapy (Eligard-leuprolide acetate) in Combination with Taxotere (docetaxel) Administered Every Three Weeks Versus Hormonal Therapy Alone Versus Deferred Th
 
Principal Investigator: Aaron Katz  
Start date: 05/15/2006
End date: 11/30/2011
to request information from Principal Investigator.
   Top of page
Phase 1 Dose-Escalation Trial of Intravesical CG0070 for Superficial Transitional Cell Carcinoma of the Bladder after Bacillus Calmette-Guerin Failure - Protocol #V-0046
 
Principal Investigator: James McKiernan  
Start date: 08/10/2005
End date: 02/28/2021
to request information from Principal Investigator.
   Top of page
Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation with Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects with a Rising PSA Following Definitive Local Therapy
 
Principal Investigator: Mitchell C. Benson  
Start date: 11/20/2007
End date: 05/31/2013
to request information from Principal Investigator.
   Top of page
SELECT - Selenium and Vitamin E Cancer Prevention Trial (SELECT)
 
Principal Investigator: Mitchell C. Benson  
Start date: 06/01/2000
End date: 05/31/2013
to request information from Principal Investigator.
   Top of page
UCOP - Urological Cancer Outreach Program Purchase Service Agreement
 
Principal Investigator: Mitchell C. Benson  
Start date: 04/22/1999
End date: 12/31/2009
to request information from Principal Investigator.
   Top of page
Copyright © 1997-2009 Columbia University Medical Center